J. Schellens

发表

Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab

C. Damen, Weibin Chen, A. Chakraborty, 2009, Journal of the American Society for Mass Spectrometry.

Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression.

J. Schellens, P. Hershberger, T. Mcguire, 2002, Molecular cancer therapeutics.

Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy.

J. Schellens, M. Verheij, W. V. van Blitterswijk, 2007, Cancer treatment reviews.

Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.

J. Wanders, E. Raymond, J. Schellens, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients

J. Schellens, H. Rosing, J. Beijnen, 2002, Anti-cancer drugs.

E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer.

J. Schellens, J. Beijnen, C. van Kesteren, 2002, Anti-cancer drugs.

Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine.

J. Verweij, J. Schellens, W. Loos, 1996, Journal of chromatography. B, Biomedical applications.

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients

J. Schellens, H. Rosing, J. Beijnen, 2017, Cancer Chemotherapy and Pharmacology.

Extensive Metabolism and Hepatic Accumulation of Gemcitabine After Multiple Oral and Intravenous Administration in Mice

J. Schellens, J. Beijnen, D. Pluim, 2008, Drug Metabolism and Disposition.

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry

J. Schellens, J. Beijnen, R. C. Garner, 2007, Investigational New Drugs.

Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles

J. Schellens, J. Beijnen, P. Borst, 2004, Cancer Research.

Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

J. Schellens, G. Reid, O. van Tellingen, 2002, Molecular cancer therapeutics.

The Effect of St John’s Wort on the Pharmacokinetics of Docetaxel

J. Schellens, H. Rosing, J. Beijnen, 2013, Clinical Pharmacokinetics.

Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies.

S. Sleijfer, P. V. van Diest, E. Cuppen, 2017, The oncologist.

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

A. Ashworth, A. Tutt, J. Carmichael, 2009, The New England journal of medicine.

Drug interactions in oncology.

J. Schellens, J. Beijnen, 2004, The Lancet. Oncology.

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis

J. Schellens, J. Beijnen, T. Dorlo, 2018, Front. Cell. Infect. Microbiol..

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.

A. V. van Kuilenburg, J. Schellens, H. Rosing, 2018, The Lancet. Oncology.

Procedures and practices for the validation of bioanalytical methods using dried blood spots: a review.

J. Schellens, H. Rosing, J. Beijnen, 2014, Bioanalysis.

Application of PET/CT in the development of novel anticancer drugs.

J. Schellens, J. Beijnen, D. Boss, 2008, The oncologist.

The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

Jos H Beijnen, J. Schellens, J. Beijnen, 2003, Cancer research.

Liquid chromatography-tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma.

J. Schellens, J. Beijnen, J. S. Lagas, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology.

J. Schellens, J. Beijnen, I. Meijerman, 2007, Cancer treatment reviews.

MIDAZOLAM AND CYCLOSPORIN A METABOLISM IN TRANSGENIC MICE WITH LIVER-SPECIFIC EXPRESSION OF HUMAN CYP3A4

J. Schellens, J. Beijnen, A. V. van Herwaarden, 2005, Drug Metabolism and Disposition.

Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.

J. Schellens, J. Beijnen, A. Huitema, 2006, Basic & clinical pharmacology & toxicology.

Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.

J. Schellens, W. Dalton, J. Allen, 2000, Cancer research.

Pharmacokinetic–pharmacodynamic Guided Trial Design in Oncology

J. Schellens, J. Beijnen, C. van Kesteren, 2003, Investigational New Drugs.

Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.

J. Schellens, J. Beijnen, P. Breedveld, 2006, Trends in pharmacological sciences.

Detection of Single Nucleotide Polymorphisms in theABCG2Gene in a Dutch Population

J. Schellens, J. Beijnen, B. Koeleman, 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

M. J. van de Vijver, J. Schellens, M. Vijver, 2001, Cancer research.

Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.

J. Schellens, D. Pluim, R. V. van Waardenburg, 1999, Cancer research.

Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study

J. Schellens, J. Beijnen, R. Mathijssen, 2019, Pharmaceutical Research.

Hepatotoxicity and metabolism of trabectedin: a literature review.

J. Schellens, J. Beijnen, J. Beumer, 2005, Pharmacological research.

Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.

J. Schellens, J. Beijnen, C. van Kesteren, 2003, Anti-cancer drugs.

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

J. Schellens, H. Rosing, J. Beijnen, 2002, Anti-cancer drugs.

Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer

D. Richel, J. Schellens, J. Wilmink, 2015, Cancer Chemotherapy and Pharmacology.

Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry.

Marie-Christine W. Gast, Jos H Beijnen, Marie-Christine W Gast, 2006, Trends in pharmacological sciences.

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites

S. Linn, J. Schellens, J. Beijnen, 2013, BMC Cancer.

The Impact of Structural Uncertainty on Cost-Effectiveness Models for Adjuvant Endocrine Breast Cancer Treatments: the Need for Disease-Specific Model Standardization and Improved Guidance

J. Schellens, J. Severens, A. Huitema, 2013, PharmacoEconomics.

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

Jos H. Beijnen, Ron J. Keizer, Alwin D. R. Huitema, 2010, Clinical pharmacokinetics.

PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line

J. Schellens, J. Beijnen, I. Meijerman, 2009, Cancer Chemotherapy and Pharmacology.

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam

J. Wanders, C. Punt, E. Raymond, 2005, Investigational New Drugs.

Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.

J. Schellens, J. Beijnen, O. van Tellingen, 2002, Cancer research.

CYP2C9 and CYP2C19 Polymorphic Forms Are Related to Increased Indisulam Exposure and Higher Risk of Severe Hematologic Toxicity

J. Schellens, J. Beijnen, A. Zandvliet, 2007, Clinical Cancer Research.

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

J. Schellens, J. Beijnen, A. Huitema, 2017, Clinical pharmacology and therapeutics.

Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.

M. J. van den Bent, J. Verweij, J. Schellens, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Symptoms and treatment in cancer therapy-induced early menopause.

J. Schellens, J. Beijnen, A. Boekhout, 2006, The oncologist.

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

M. Zauderer, J. Schellens, D. Fennell, 2019, Investigational New Drugs.

Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices.

A. C. Dubbelman, J. Schellens, H. Rosing, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study

J. Schellens, H. Rosing, J. Beijnen, 2008, Clinical Cancer Research.

Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1)

A. Jager, J. Bono, J. Schellens, 2019, Investigational New Drugs.

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial

S. Linn, J. Schellens, H. van Tinteren, 2016, Trials.

Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2)

J. Schellens, A. Schinkel, K. Mohrmann, 2005, Cancer Chemotherapy and Pharmacology.

From Mouse to Man: Predictions of Human Pharmacokinetics of Orally Administered Docetaxel From Preclinical Studies

J. Schellens, J. Beijnen, A. Schinkel, 2012, Journal of clinical pharmacology.

Evaluation of α2-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in Preclinical and Clinical Studies

J. Wanders, J. Schellens, J. Beijnen, 2011, The AAPS Journal.

PK/PD Model of Indisulam and Capecitabine: Interaction Causes Excessive Myelosuppression

J. Schellens, J. Beijnen, G. Milano, 2008, Clinical pharmacology and therapeutics.

The effect of grape seed extract on the pharmacokinetics of dextromethorphan in healthy volunteers

J. Schellens, J. Beijnen, A. Goey, 2013, European Journal of Clinical Pharmacology.

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin

J. Wanders, J. Schellens, J. Beijnen, 2013, British journal of clinical pharmacology.

Population Pharmacokinetics and Pharmacodynamics for Treatment Optimization in Clinical Oncology

J. Schellens, J. Beijnen, A. Zandvliet, 2008, Clinical pharmacokinetics.

Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors

D. Mould, J. Schellens, H. Rosing, 2002, Clinical pharmacology and therapeutics.

Detection of Colorectal Cancer by Serum and Tissue Protein Profiling: A Prospective Study in a Population at Risk

L. Wessels, J. Schellens, J. Beijnen, 2008, Biomarker insights.

Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut

J. Schellens, J. Beijnen, O. van Tellingen, 2002, Cancer Chemotherapy and Pharmacology.

Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.

J. Schellens, H. Rosing, J. Beijnen, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel

J. Schellens, J. Beijnen, W. W. ten Bokkel Huinink, 2001, European Journal of Clinical Pharmacology.

Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093)

J. Schellens, H. Rosing, J. Beijnen, 2004, Cancer Chemotherapy and Pharmacology.

Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice

J. Schellens, J. Beijnen, O. van Tellingen, 2004, Investigational New Drugs.

Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood–Brain Barrier Using Elacridar and 11C-Erlotinib PET

A. Lammertsma, M. Yaqub, J. Schellens, 2017, The Journal of Nuclear Medicine.

Review on the analysis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and its phase I and phase II metabolites in biological matrices, foodstuff and beverages.

J. Schellens, H. Rosing, J. Beijnen, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug

J. Schellens, J. Beijnen, E. Brandon, 2004, Investigational New Drugs.

Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar

J. Schellens, J. Beijnen, A. Huitema, 2017, Drug Delivery and Translational Research.

Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar☆

J. Schellens, H. Rosing, J. Beijnen, 2016, Journal of pharmaceutical analysis.

Quantification of taxanes in biological matrices: a review of bioanalytical assays and recommendations for development of new assays.

J. Schellens, H. Rosing, J. Beijnen, 2014, Bioanalysis.

Evaluation of a Pharmacology-Driven Dosing Algorithm of 3-Weekly Paclitaxel Using Therapeutic Drug Monitoring

J. Schellens, J. Beijnen, U. Jaehde, 2012, Clinical Pharmacokinetics.

Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group

H. Hollema, A. Boddy, D. Richel, 2007, Clinical Cancer Research.

Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study.

J. Schellens, H. Rosing, J. Beijnen, 2007, British journal of clinical pharmacology.

Quantitative Effect of Gender, Age, Liver Function, and Body Size on the Population Pharmacokinetics of Paclitaxel in Patients with Solid Tumors

J. Schellens, J. Beijnen, A. Huitema, 2006, Clinical Cancer Research.

Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.

S. Rodenhuis, J. Schellens, J. Beijnen, 2005, British journal of clinical pharmacology.

Development and validation of a method to determine the unbound paclitaxel fraction in human plasma.

J. Schellens, H. Rosing, J. Beijnen, 2004, Analytical biochemistry.

A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979).

A. Harris, L. Aarons, J. Schellens, 2003, British journal of clinical pharmacology.

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

L. Grochow, J. Verweij, J. Schellens, 2002, Journal of the National Cancer Institute.

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients

J. Schellens, J. Beijnen, J. Schellens, 1999, British Journal of Cancer.

In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectidin®), a novel marine anti-cancer drug

J. Schellens, J. Beijnen, E. Brandon, 2006, Investigational New Drugs.

In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction

J. Schellens, J. Beijnen, E. Brandon, 2005, Anti-cancer drugs.

Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours

J. Schellens, J. Beijnen, G. Sanderink, 2005, Cancer Chemotherapy and Pharmacology.

Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview.

J. Schellens, J. Beijnen, C. M. Kruijtzer, 2002, The oncologist.

Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection.

J. Verweij, J. Schellens, A. Sparreboom, 1997, Journal of Chromatography B: Biomedical Sciences and Applications.

Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.

J. Schellens, J. Beijnen, W. W. ten Bokkel Huinink, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The bioanalysis of trastuzumab in human serum using precipitate-enhanced ellipsometry.

C. Damen, J. Schellens, H. Rosing, 2009, Analytical biochemistry.

Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients

J. Schellens, J. Beijnen, M. Deenen, 2013, Therapeutic advances in medical oncology.

DNA-based drug interactions of cisplatin.

J. Schellens, J. Beijnen, R. V. van Waardenburg, 2002, Cancer treatment reviews.

Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel–cisplatin–topotecan in a phase I study

J. Schellens, J. Beijnen, D. Pluim, 2002, Anti-cancer drugs.

Concise drug review: pazopanib and axitinib.

J. Schellens, J. Beijnen, R. van Geel, 2012, The oncologist.

Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors

A. C. Dubbelman, J. Schellens, J. Beijnen, 2012, Cancer Chemotherapy and Pharmacology.

Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite.

J. Schellens, J. Beijnen, M. Vlaming, 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies

N. Agarwal, J. Schellens, R. Kurzrock, 2015, Clinical Cancer Research.

Clinical Relevance: Drug–Drug Interactions, Pharmacokinetics, Pharmacodynamics, and Toxicity

J. Schellens, J. Beijnen, R. Mazzanti, 2006 .

Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure–response relationships

J. Schellens, J. Beijnen, N. Saravia, 2018, Journal of Antimicrobial Chemotherapy.

Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2′,2′‐difluorodeoxyuridine and their nucleotides

J. Schellens, H. Rosing, J. Beijnen, 2018, British journal of clinical pharmacology.

Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.

J. Schellens, H. Rosing, J. Beijnen, 2016, British journal of clinical pharmacology.

Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Multiparameter Flow Cytometry Assay for Quantification of Immune Cell Subsets, PD‐1 Expression Levels and PD‐1 Receptor Occupancy by Nivolumab and Pembrolizumab

J. Schellens, J. Beijnen, D. Pluim, 2019, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Comparison of Two Immortalized Human Cell Lines to Study Nuclear Receptor-Mediated CYP3A4 Induction

J. Schellens, J. Beijnen, I. Meijerman, 2008, Drug Metabolism and Disposition.

Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer

J. Schellens, H. Rosing, J. Beijnen, 2007, Cancer Chemotherapy and Pharmacology.

SATURABLE BINDING OF INDISULAM TO PLASMA PROTEINS AND DISTRIBUTION TO HUMAN ERYTHROCYTES

J. Schellens, J. Beijnen, A. Zandvliet, 2006, Drug Metabolism and Disposition.

Pharmacokinetic Drug–Drug Interaction of the Novel Anticancer Agent E7070 and Acenocoumarol

J. Schellens, J. Beijnen, H. D. van den Bongard, 2004, Investigational New Drugs.

DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin.

J. Schellens, J. Beijnen, D. Pluim, 2003, Biochemical pharmacology.

Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma.

J. Schellens, J. Beijnen, R. Sparidans, 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

P‐glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel

J. Schellens, H. Rosing, J. Beijnen, 2013, International journal of cancer.

Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.

J. Schellens, J. Beijnen, P. Baas, 2011, Lung cancer.

Prediction of treatment outcome by cisplatin‐DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin‐radiation (RADPLAT)

H. Bartelink, F. Hoebers, J. Schellens, 2006, International journal of cancer.

The combined use of radiotherapy and chemotherapy in the treatment of solid tumours.

H. Bartelink, J. Schellens, M. Verheij, 2002, European journal of cancer.

Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples

J. Schellens, J. Beijnen, O. van Tellingen, 2003, Laboratory animals.

Radiosensitization of Squamous Cell Carcinoma by the Alkylphospholipid Perifosine in Cell Culture and Xenografts

J. Schellens, A. Begg, M. Verheij, 2006, Clinical Cancer Research.

Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma.

J. Schellens, J. Beijnen, A. Schinkel, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent

J. Schellens, J. Beijnen, D. Pluim, 2004, Clinical Cancer Research.

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients

J. Schellens, H. Rosing, J. Beijnen, 2017, Cancer Chemotherapy and Pharmacology.

Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials.

J. Schellens, J. Beijnen, E. Voest, 2011, Cancer treatment reviews.

Strategies to target drugs to gliomas and CNS metastases of solid tumors

J. Schellens, J. Beijnen, A. Huitema, 2016, Journal of Neurology.

Frequent expression of the multi‐drug resistance‐associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP‐21 monoclonal antibody in paraffin‐embedded material

I. Catalá, J. Schellens, M. Izquierdo, 2002, The Journal of pathology.

Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate.

E. Westerhout, Mohamed Hamdi, J. Schellens, 2015, Journal of pharmaceutical and biomedical analysis.

Reply to T. Magnes et al.

J. Schellens, J. Beijnen, J. Severens, 2016, Journal of Clinical Oncology.

Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.

J. Schellens, H. Guchelaar, H. Gelderblom, 2018, European journal of cancer.

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.

S. Jaeger, J. Schellens, H. Lenz, 2017, Cancer discovery.

Phase I Pharmacokinetic Study of the Safety and Tolerability of Lapatinib (GW572016) in Combination with Oxaliplatin/Fluorouracil/Leucovorin (FOLFOX4) in Patients with Solid Tumors

D. Richel, J. Schellens, J. Beijnen, 2007, Clinical Cancer Research.

Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration.

J. Schellens, J. Beijnen, I. E. Kuppens, 2004, Clinical colorectal cancer.

Organic Anion-Transporting Polypeptide 1B1 Mediates Transport of Gimatecan and BNP1350 and Can Be Inhibited by Several Classic ATP-Binding Cassette (ABC) B1 and/or ABCG2 Inhibitors

J. Schellens, J. Beijnen, E. van de Steeg, 2009, Drug Metabolism and Disposition.

Clinical and Pharmacologic Study of the Novel Prodrug Delimotecan (MEN 4901/T-0128) in Patients with Solid Tumors

J. Schellens, J. Beijnen, E. Voest, 2008, Clinical Cancer Research.

Dose-Finding Phase I Clinical and Pharmacokinetic Study of Orally Administered Irinotecan in Patients with Advanced Solid Tumors

J. Schellens, J. Beijnen, J. Bonneterre, 2006, Clinical Cancer Research.

High-Performance Liquid Chromatographic Analysis of the Anticancer Drug Irinotecan (CPT-11) and Its Active Metabolite SN-38 in Human Plasma

J. Schellens, H. Rosing, J. Beijnen, 2003, Therapeutic drug monitoring.

A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.

A. V. van Kuilenburg, J. Schellens, H. Rosing, 2019, European journal of cancer.

Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.

J. Schellens, E. Zuhowski, M. Egorin, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Novel Clinical Trial Designs for Innovative Therapies

J. Schellens, J. Beijnen, J. Schellens, 2009, Clinical pharmacology and therapeutics.

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.

J. Schellens, P. Wielinga, D. Pluim, 2005, Cancer research.

A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients

J. Schellens, J. Beijnen, E. Voest, 2007, Clinical Cancer Research.

Advances in Brief Overexpression of the BCRP / MXR / ABCP Gene in a Topotecan-selected Ovarian Tumor Cell Line 1

J. Schellens, D. Pluim, R. C. A. M. Waardenburg, 1999 .

Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

M. Vijver, J. Schellens, M. Vijver, 2001, Cancer research.

Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel.

D. Richel, J. Schellens, H. Rosing, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1−/−/Mdr1a/1b−/− (triple-knockout) and wild-type mice

J. Schellens, J. Beijnen, O. van Tellingen, 2008, Molecular Cancer Therapeutics.

Severe Lactic Acidosis in a Diabetic Patient after Ethanol Abuse and Floor Cleaner Intake

J. Schellens, J. Beijnen, A. Huitema, 2014, Basic & clinical pharmacology & toxicology.

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial

J. Schellens, J. Beijnen, R. Mathijssen, 2017, Clinical Pharmacokinetics.

Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

S. Rodenhuis, J. Schellens, J. Beijnen, 2009, Cancer Chemotherapy and Pharmacology.

Flat Dosing of Carboplatin Is Justified in Adult Patients with Normal Renal Function

S. Rodenhuis, J. Schellens, J. Beijnen, 2006, Clinical Cancer Research.

Relationship between cisplatin administration and the development of ototoxicity.

J. Schellens, J. Beijnen, P. Baas, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: an IPD meta-analysis.

U. Amstutz, J. Schellens, S. Aebi, 2019, Pharmacological research.

The Effect of Food on the Pharmacokinetics of S-1 after Single Oral Administration to Patients with Solid Tumors

G. Peters, G. Giaccone, J. Schellens, 2004, Clinical Cancer Research.

Essential medicines for breast cancer in low and middle income countries

J. Schellens, H. Leufkens, A. Mantel‐Teeuwisse, 2015, BMC Cancer.

Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study

A. V. van Kuilenburg, J. Maring, J. Schellens, 2022, Clinical pharmacology and therapeutics.

The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies.

S. Sleijfer, J. Schellens, E. Voest, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Breakthrough therapy-designated oncology drugs: are they rightfully criticized?

J. Schellens, A. Pasmooij, V. Stoyanova-Beninska, 2020, Drug discovery today.

Emerging Drug Treatments for Solid Tumours

J. Verweij, J. Schellens, L. Pronk, 2012, Drugs.

Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2)

A. Jager, J. Bono, J. Schellens, 2019, Investigational New Drugs.

A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir

J. Schellens, H. Rosing, J. Beijnen, 2019, Clinical Cancer Research.

A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir.

J. Schellens, H. Rosing, J. Beijnen, 2017, European journal of cancer.

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.

A. Oza, G. Shapiro, J. Schellens, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

R. Plummer, J. Verweij, J. Schellens, 2014, Clinical Cancer Research.

Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.

J. Schellens, J. Beijnen, A. Huitema, 2013, Gynecologic oncology.

Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors.

R. Plummer, J. Verweij, J. Schellens, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole

J. Wanders, J. Schellens, J. Beijnen, 2013, Investigational New Drugs.

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment

J. Wanders, J. Schellens, J. Beijnen, 2012, Cancer Chemotherapy and Pharmacology.

Serum proteomics and disease-specific biomarkers of patients with advanced gastric cancer.

J. Schellens, J. Beijnen, H. Helgason, 2010, Oncology letters.

Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors

J. Schellens, H. Rosing, J. Beijnen, 2010, Investigational New Drugs.

A Phase I Safety and Pharmacologic Study of a Twice Weekly Dosing Regimen of the Oral Taxane BMS-275183

G. Giaccone, J. Schellens, E. Heath, 2007, Clinical Cancer Research.

Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.

S. Rodenhuis, J. Schellens, A. Huitema, 2001, British journal of clinical pharmacology.

Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.

J. Schellens, H. Rosing, J. Beijnen, 1999, Pharmacological research.

Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.

J. Verweij, J. Schellens, D. V. Von Hoff, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.

J. Verweij, J. Schellens, D. V. Von Hoff, 1998, European journal of cancer.

A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer

M. J. van den Bent, J. Verweij, J. Schellens, 1997, Cancer Chemotherapy and Pharmacology.

Identification of serum proteins as prognostic and predictive markers of colorectal cancer using surface enhanced laser desorption ionization-time of flight mass spectrometry.

J. Schellens, J. Beijnen, H. Helgason, 2010, Oncology reports.

Bioanalytical liquid chromatography‐tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates

J. Schellens, J. Beijnen, A. Schinkel, 2018, Journal of pharmaceutical and biomedical analysis.

Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel

S. Rodenhuis, H. V. van Boven, J. Schellens, 2007, Investigational New Drugs.

Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.

J. Schellens, J. Beijnen, P. Baas, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Dihydrofolate Reductase/Thymidylate Synthase Fine-Tunes the Folate Status and Controls Redox Homeostasis in Plants

J. Schellens, F. Rébeillé, D. Van Der Straeten, 2017, Plant Cell.

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

J. Schellens, Sunil Sharma, A. Naing, 2020, Journal for ImmunoTherapy of Cancer.

A phase 1 dose-escalation study of anti-HER3 monoclonal antibody LJM716 in combination with trastuzumab in patients with HER2-overexpressing metastatic breast or gastric cancer.

J. Baselga, D. Juric, J. Schellens, 2014 .

Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors

L. Sequist, J. Schellens, P. LoRusso, 2014 .

Effect of Chinese herbs on CYP3A4 activity and expression in vitro.

J. Schellens, J. Beijnen, I. Meijerman, 2013, Journal of ethnopharmacology.

Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer

J. Schellens, J. Geenen, 2017, Clinical Cancer Research.

Thymidylate synthase maintains the de-differentiated state of aggressive breast cancers

I. Asangani, S. A. K. Rasheed, J. Schellens, 2018, bioRxiv.

Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?

E. Smit, J. Schellens, J. Beijnen, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.

H. Groen, E. Smit, J. Schellens, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma.

J. Schellens, J. Beijnen, A. Schinkel, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC

P. Jänne, J. Engelman, J. Schellens, 2008 .

Changing costs of metastatic non small cell lung cancer in the Netherlands.

J. Schellens, W. Keusters, G. Frederix, 2017, Lung cancer.

Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique.

J. Schellens, J. Beijnen, B. Nuijen, 2016, Cancer treatment reviews.

Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study

S. Sleijfer, H. Horlings, E. Cuppen, 2017, Oncotarget.

Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor

J. Schellens, J. Beijnen, T. Stephens, 2010, Cancer Chemotherapy and Pharmacology.

The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate

J. Schellens, J. Beijnen, R. Mazzanti, 2007, Cancer Chemotherapy and Pharmacology.

SELDI-TOF MS serum protein profiling predicts poor prognosis in renal cancer patients

J. Schellens, J. Beijnen, E. Voest, 2007 .

First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC).

J. Schellens, J. Tabernero, M. Alsina, 2017 .

Ciprofloxacin Strongly Inhibits Clozapine Metabolism

J. Schellens, J. Beijnen, M. Söhne, 2009, Clinical Drug Investigation.

Bioanalytical LC-MS/MS validation of therapeutic drug monitoring assays in oncology.

J. Schellens, H. Rosing, J. Beijnen, 2019, Biomedical chromatography : BMC.

No pharmacokinetic drug–drug interaction between nevirapine and paclitaxel

J. Schellens, J. Beijnen, A. Huitema, 2005, Anti-cancer drugs.

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

J. Schellens, J. Beijnen, A. Huitema, 2017, Cancer Chemotherapy and Pharmacology.

Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues

J. Schellens, J. Beijnen, D. Pluim, 2013, Clinical Cancer Research.

Metabolite profiling of 14C-omacetaxine mepesuccinate in plasma and excreta of cancer patients

J. Schellens, H. Rosing, E. Hellriegel, 2016, Xenobiotica; the fate of foreign compounds in biological systems.

HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC METHODS FOR THE DETERMINATION OF A NOVEL POLYMER-BOUND PACLITAXEL DERIVATIVE AND FREE PACLITAXEL IN HUMAN PLASMA

J. Schellens, H. Rosing, J. Beijnen, 2000 .

Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.

D. Richel, J. Schellens, H. Rosing, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted toxins

J. Schellens, J. Beijnen, G. D. de Gast, 1999 .

Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours.

H. Bartelink, H. Sindermann, J. Schellens, 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.

J. Schellens, J. Beijnen, G. Wolbink, 2016, The oncologist.

Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer

J. Schellens, J. Beijnen, P. Baas, 2005, Anti-cancer drugs.

Bioanalytical methods for determination of tamoxifen and its phase I metabolites: a review.

J. Schellens, H. Rosing, J. Beijnen, 2010, Analytica chimica acta.

Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820

J. Wanders, J. Schellens, J. Beijnen, 2009, Investigational New Drugs.

A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

A. Oza, G. Shapiro, J. Schellens, 2010 .

A phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

A. Oza, G. Shapiro, J. Schellens, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer Patients

D. Richel, J. Schellens, J. Beijnen, 2007, Clinical pharmacokinetics.

Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152.

J. Schellens, J. Beijnen, E. Voest, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers

J. Schellens, J. Beijnen, M. Joerger, 2006, European Journal of Clinical Pharmacology.

Dose-response relationship in phase I clinical trials: A European Drug Development Network (EDDN) collaboration study.

R. Plummer, J. Verweij, J. Schellens, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs.

J. Schellens, H. Rosing, J. Beijnen, 2011, Mass spectrometry reviews.

Systematic Review of Biomarkers To Monitor Therapeutic Response in Leishmaniasis

J. Schellens, J. Beijnen, P. D. de Vries, 2014, Antimicrobial Agents and Chemotherapy.

Cancer Resistance Protein in Clinical Drug-Drug Interactions Methotrexate and Benzimidazoles : Potential Role for Breast Mechanism of the Pharmacokinetic Interaction between Updated

J. Schellens, J. Beijnen, P. Borst, 2004 .

The Accumulation of Topotecan in 9L Glioma and in Brain Parenchyma with and without Dexamethasone Administration

M. J. van den Bent, J. Schellens, W. Loos, 2004, Journal of Neuro-Oncology.

Cancer Therapy : Preclinical Abcc 4 Together with Abcb 1 and Abcg 2 Form a Robust Cooperative Drug Ef fl ux System That Restricts the Brain Entry of Camptothecin Analogues

J. Schellens, J. Beijnen, D. Pluim, 2013 .

Taxanes: old drugs, new oral formulations.

J. Schellens, J. Beijnen, B. Nuijen, 2013, European journal of pharmacology.

Intravenous‐to‐Oral Switch in Anticancer Chemotherapy: A Focus on Docetaxel and Paclitaxel

J. Schellens, J. Beijnen, J. Schellens, 2010, Clinical pharmacology and therapeutics.

Co-administration of cyclosporin enables oral therapy with paclitaxel

J. Schellens, H. Rosing, J. Beijnen, 1998, The Lancet.

Quantitative analysis of the P-glycoprotein inhibitor Elacridar (GF120918) in human and dog plasma using liquid chromatography with tandem mass spectrometric detection.

J. Schellens, H. Rosing, J. Beijnen, 2004, Journal of mass spectrometry : JMS.

Determination of cyclosporin A in human and mouse plasma by reversed-phase high-performance liquid chromatography.

J. Schellens, J. Beijnen, O. van Tellingen, 2001, Journal of chromatography. B, Biomedical sciences and applications.

A rapid and simple HPLC-UV method for the determination of inhibition characteristics of farnesyl transferase inhibitors.

J. Schellens, H. Rosing, J. Beijnen, 2006, Biomedical chromatography : BMC.

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

J. Verweij, J. Schellens, H. Rosing, 1995, Cancer Chemotherapy and Pharmacology.

Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1

J. Verweij, J. Schellens, M. Maliepaard, 1997, Cancer Chemotherapy and Pharmacology.

Model-Based Evaluation and Optimization of Cardiac Monitoring Protocols for Adjuvant Treatment of Breast Cancer with Trastuzumab

J. Schellens, J. Beijnen, A. Huitema, 2012, Pharmaceutical Research.

Capecitabine‐based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency

A. V. van Kuilenburg, L. Zoetekouw, J. Schellens, 2018, International journal of cancer.

Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology.

J. Schellens, J. Beijnen, R. Sparidans, 2016, Journal of pharmaceutical and biomedical analysis.

Screening for polymorphisms in the PXR gene in a Dutch population

J. Schellens, J. Beijnen, M. Deenen, 2006, European Journal of Clinical Pharmacology.

Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens

J. Schellens, J. Gietema, A. Huitema, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

Factors Affecting Long-Term Safety of Trastuzumab in Patients with Early HER2-Positive Breast Cancer

J. Schellens, J. Beijnen, A. Boekhout, 2014 .

Enrichment of Circulating Endothelial Cells by CD34 Microbeads Followed by Enumeration Using Flow Cytometry

J. Schellens, J. Beijnen, F. Stuurman, 2017, Thrombosis and Haemostasis.

Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.

H. Keizer, J. Schellens, J. Beijnen, 2000, British journal of clinical pharmacology.

Capecitabine induces severe angina-like chest pain.

J. Schellens, J. Beijnen, H. Boot, 2004, Annals of internal medicine.

The clinical pharmacology of alkylating agents in high-dose chemotherapy.

S. Rodenhuis, J. Schellens, A. Huitema, 2000, Anti-cancer drugs.

The bioanalysis of the monoclonal antibody trastuzumab by high-performance liquid chromatography with fluorescence detection after immuno-affinity purification from human serum.

C. Damen, J. Schellens, H. Rosing, 2009, Journal of pharmaceutical and biomedical analysis.

Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice

J. Schellens, H. Rosing, J. Beijnen, 2010, Investigational New Drugs.

OATP1B1 mediates transport of gimatecan and BNP1350 and can be inhibited by several classical ABCB1 and/or ABCG2 inhibitors

J. Schellens, J. Beijnen, A. Schinkel, 2008 .

Trabectedin (ET-743, Yondelis™) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype

J. Schellens, J. Beijnen, J. Beumer, 2007, Investigational New Drugs.

Chapter 2 Carcinogen and anti-cancer drug transport by Mrp 2 in vivo : studies using Mrp 2 ( Abcc 2 ) knockout mice

J. Schellens, H. Rosing, E. Wagenaar, 2009 .

Metabolism of paclitaxel in mice

J. Schellens, J. Beijnen, O. van Tellingen, 2003, Anti-cancer drugs.

No relation between docetaxel administration route and high‐grade diarrhea incidence

J. Schellens, H. Rosing, J. Beijnen, 2020, Pharmacology research & perspectives.

Food‐effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers

J. Schellens, H. Rosing, J. Beijnen, 2018, British journal of clinical pharmacology.

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs

J. Schellens, J. Beijnen, T. Dorlo, 2017, Clinical Pharmacokinetics.

Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.

J. Schellens, H. Rosing, M. Hillebrand, 2013, Biomedical chromatography : BMC.

Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid

J. Schellens, J. Beijnen, D. Pluim, 2019, Journal of pharmaceutical and biomedical analysis.

Phase I and pharmacologic study of enzastaurin HCl, gemcitabine and cisplatin.

J. Schellens, J. Beijnen, E. Voest, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir

J. Schellens, J. Beijnen, A. Huitema, 2020, Investigational New Drugs.

A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development

J. Schellens, J. Beijnen, A. Huitema, 2019, Journal of clinical pharmacology.

Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model

J. Schellens, H. Rosing, J. Beijnen, 2016, International journal of cancer.

Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer

J. Schellens, J. Beijnen, S. Rottenberg, 2015, The AAPS Journal.

Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel – a review

J. Schellens, J. Beijnen, Vincent A de Weger, 2014, Anti-cancer drugs.

Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation

J. Schellens, H. Rosing, J. Beijnen, 2014, British Journal of Cancer.

Coadministration of Ritonavir Strongly Enhances the Apparent Oral Bioavailability of Docetaxel in Patients with Solid Tumors

J. Schellens, H. Rosing, J. Beijnen, 2009, Clinical Cancer Research.

Metabolism of docetaxel in mice

J. Schellens, J. Beijnen, M. Hillebrand, 2005, Cancer Chemotherapy and Pharmacology.

Development and validation of a LC-MS/MS method for the in vitro analysis of 1-hydroxymidazolam in human liver microsomes: application for determining CYP3A4 inhibition in complex matrix mixtures.

J. Schellens, H. Rosing, J. Beijnen, 2013, Biomedical chromatography : BMC.

Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry.

J. Schellens, J. Beijnen, R. Sparidans, 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Liquid chromatography-tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma.

J. Schellens, J. Beijnen, A. Schinkel, 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Development and validation of a liquid chromatography-tandem mass spectrometry assay for the analysis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and its metabolite 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-OH-PhIP) in plasma, urine, bile, intestinal contents, faeces an

J. Schellens, H. Rosing, J. Beijnen, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies.

J. Schellens, J. Beijnen, A. Schinkel, 2016, Journal of pharmaceutical and biomedical analysis.

Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies

R. Obach, J. Wanders, J. Schellens, 2010, Investigational New Drugs.

Human metabolism of [14C]indisulam following i.v. infusion in cancer patients

J. Schellens, H. Rosing, J. Beijnen, 2005, Investigational New Drugs.

Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance.

J. Verweij, J. Schellens, L. Webster, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Advances in Brief Breast Cancer Resistance Protein Is Localized at the Plasma Membrane in Mitoxantrone-and Topotecan-resistant Cell Lines 1

J. Schellens, W. Dalton, D. Ross, 2000 .

Isocratic ion-exchange chromatographic assay for the nucleotide gemcitabine triphosphate in human white blood cells.

J. Schellens, J. Beijnen, R. Sparidans, 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2006, Journal of mass spectrometry : JMS.

Retention studies of 2'-2'-difluorodeoxycytidine and 2'-2'-difluorodeoxyuridine nucleosides and nucleotides on porous graphitic carbon: development of a liquid chromatography-tandem mass spectrometry method.

J. Schellens, H. Rosing, J. Beijnen, 2009, Journal of chromatography. A.

Simultaneous quantification of 2',2'-difluorodeoxycytidine and 2',2'-difluorodeoxyuridine nucleosides and nucleotides in white blood cells using porous graphitic carbon chromatography coupled with tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2009, Rapid communications in mass spectrometry : RCM.

Dried Blood Spot Self-Sampling at Home for the Individualization of Tamoxifen Treatment: A Feasibility Study.

S. Linn, J. Schellens, H. Rosing, 2015, Therapeutic drug monitoring.

Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry.

S. Linn, J. Schellens, H. Rosing, 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing

J. Schellens, J. Beijnen, A. Huitema, 2017, Clinical Pharmacokinetics.

Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man

J. Schellens, H. Rosing, J. Beijnen, 2001, Anti-cancer drugs.

Urinary and fecal excretion of topotecan in patients with malignant solid tumours

J. Schellens, H. Rosing, J. Beijnen, 2002, Cancer Chemotherapy and Pharmacology.

Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods.

J. Schellens, H. Rosing, J. Beijnen, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines

J. Schellens, J. Beijnen, L. M. Henricks, 2016, Cancer Chemotherapy and Pharmacology.

Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography.

J. Schellens, J. Beijnen, D. Pluim, 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Cisplatin resistance and DNA repair.

J. Schellens, J. Beijnen, M. Maliepaard, 1997, Cancer Treatment Reviews.

The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor

M. J. van den Bent, J. Schellens, J. Kros, 1998, Journal of Neuro-Oncology.

Pharmacogenetic analysis of irreversible severe cisplatin‐induced nephropathy: a case report of a 27‐year‐old woman

J. Schellens, M. Deenen, G. Creemers, 2017, British journal of clinical pharmacology.

Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies

J. Rader, J. Schellens, P. Fracasso, 2004, Clinical Cancer Research.

The European Medicines Agency Review of Pazopanib for the Treatment of Advanced Renal Cell Carcinoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

J. Schellens, E. Abadie, F. Pignatti, 2011, Clinical Cancer Research.

Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS

J. Schellens, H. Rosing, J. Beijnen, 2017, Therapeutic drug monitoring.

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients

J. Schellens, J. Beijnen, R. Mathijssen, 2016, Clinical Cancer Research.

Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS.

J. Schellens, H. Rosing, J. Beijnen, 2016, Bioanalysis.

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma.

J. Schellens, J. Beijnen, R. Sparidans, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Clinical research on antiangiogenic therapy.

J. Schellens, J. Beijnen, E. Voest, 1998, Pharmacological research.

Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors .

M. Ranson, J. Schellens, F. André, 2013 .

Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors

M. Ranson, J. Schellens, F. André, 2013 .

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer

S. Linn, J. Schellens, J. Beijnen, 2019, International journal of cancer.

Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma.

J. Schellens, J. Beijnen, A. Schinkel, 2014, Biomedical chromatography : BMC.

Solubility and bioavailability improvement of pazopanib hydrochloride

J. Schellens, J. Beijnen, A. Huitema, 2018, International journal of pharmaceutics.

Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients

J. Schellens, J. Beijnen, R. Mathijssen, 2017, Clinical Pharmacokinetics.

Switching from an analogous to a stable isotopically labeled internal standard for the LC-MS/MS quantitation of the novel anticancer drug Kahalalide F significantly improves assay performance.

J. Schellens, H. Rosing, J. Beijnen, 2004, Biomedical chromatography : BMC.

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma.

M. J. van den Bent, J. Verweij, J. Schellens, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Inhibitors of mTOR.

J. Schellens, J. Beijnen, H. Gurney, 2010, The oncologist.

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.

J. Verweij, J. Schellens, W. Loos, 1998, British Journal of Cancer.

1577PGERMLINE TYMS GENOTYPE IS HIGHLY PREDICTIVE IN PATIENTS WITH ADVANCED COLORECTAL AND GASTROESOPHAGEAL CANCER INDEPENDENT OF FLUOROPYRIMIDINE PHARMACOLOGY: RESULTS FROM TWO PROSPECTIVE TRANSLATIONAL STUDIES.

J. Schellens, H. Rosing, J. Beijnen, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).

R. Bernards, C. Atreya, J. Schellens, 2014 .

Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction

J. Schellens, H. Rosing, J. Beijnen, 2013, Cancer Chemotherapy and Pharmacology.

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Gary Middleton, Takayuki Yoshino, Chloe E Atreya, 2018, Cancer discovery.

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.

Harpreet Wasan, Takayuki Yoshino, Josep Tabernero, 2019, The New England journal of medicine.

Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).

J. Desai, J. Schellens, H. Lenz, 2016 .

Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2003, Journal of mass spectrometry : JMS.

Phase I Clinical and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer

T. D. de Reijke, J. Schellens, J. Beijnen, 2005, Clinical Cancer Research.

Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2002, Journal of mass spectrometry : JMS.

Abstract LB-122: A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors

M. Hidalgo, L. Sequist, R. Camidge, 2012 .

Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database.

R. Plummer, J. Verweij, J. Schellens, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.

J. Schellens, A. Italiano, S. Piha-Paul, 2018 .

Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.

Y. Bang, J. Schellens, J. Beijnen, 2015, British journal of clinical pharmacology.

LBA-07Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)

C. Atreya, M. Ducreux, J. Schellens, 2015 .

Treatment Algorithm for Homozygous or Compound Heterozygous DPYD Variant Allele Carriers With Low-Dose Capecitabine.

A. V. van Kuilenburg, J. Schellens, H. Guchelaar, 2017, JCO precision oncology.

Running title : Complete DPD deficiency caused by a novel DPYD genotype Article category : Cancer therapy and prevention Metadata : Word count : 2122

L. Zoetekouw, J. Schellens, H. Rosing, 2017 .

Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial.

R. Greil, P. Wen, F. D. De Braud, 2019, Journal of Clinical Oncology.

Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)

S. Jaeger, C. Atreya, M. Ducreux, 2016 .

Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents.

J. Schellens, J. Beijnen, S. Leijen, 2010, Current clinical pharmacology.

A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen

S. Rodenhuis, J. Schellens, J. Beijnen, 1999, Cancer Chemotherapy and Pharmacology.

Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.

J. Verweij, J. Schellens, G. Stoter, 1995, British Journal of Cancer.

Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro

A. W. Boersma, J. Verweij, J. Schellens, 1998, Cancer Chemotherapy and Pharmacology.

Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.

J. Schellens, J. Beijnen, W. W. ten Bokkel Huinink, 1998, Pharmacy World and Science.

Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.

J. Verweij, J. Schellens, D. V. Von Hoff, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved 32P-postlabelling assay for the quantification of the major platinum-DNA adducts.

M. Welters, R. Baan, J. Schellens, 1997, Carcinogenesis.

Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry

J. Schellens, J. Beijnen, M. Tibben, 2000, Fresenius' journal of analytical chemistry.

Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma

J. Schellens, J. Beijnen, A. Huitema, 2005, Cancer Chemotherapy and Pharmacology.

Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites?

J. Schellens, H. Rosing, J. Beijnen, 2011, Fundamental & clinical pharmacology.

Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature.

W. M. Smit, J. Schellens, J. Beijnen, 2009, The oncologist.

Gemcitabine metabolite, 2’,2’-difluorodeoxyuridine (dFdU), can be phosphorylated and incorporated into nucleic acids

J. Schellens, J. Beijnen, D. Pluim, 2007 .

Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.

J. Verweij, J. Schellens, W. Loos, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F

J. Schellens, J. Beijnen, J. Jimeno, 2001, Anti-cancer drugs.

Weekly high-dose cisplatin in malignant pleural mesothelioma.

J. Verweij, J. Schellens, G. Stoter, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of PERItoneal disease in Stomach Cancer with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: PERISCOPE I initial results

J. Schellens, K. Sikorska, J. V. van Sandick, 2020, The British journal of surgery.

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)

J. Schellens, J. Beijnen, A. Zandvliet, 2011, Investigational New Drugs.

LBA-08Results of a phase 1b study of the selective BRAF V600 inhibitor encorafenib in combination with cetuximab alone or cetuximab + alpelisib for treatment of patients with advanced BRAF-mutant metastatic colorectal cancer

S. Jaeger, J. Schellens, H. Lenz, 2015 .

Homologous recombination is a highly conserved determinant of the synergistic cytotoxicity between cisplatin and DNA topoisomerase I poisons.

J. Schellens, M. Bjornsti, J. Brouwer, 2004, Molecular cancer therapeutics.

Antineoplastic Agents

J. Verweij, J. Schellens, E. Meerten, 1995, Drug safety.

The bioanalysis of vinorelbine and 4-O-deacetylvinorelbine in human and mouse plasma using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass-spectrometry.

C. Damen, J. Schellens, H. Rosing, 2009, Biomedical chromatography : BMC.

A sensitive assay for the quantitative analysis of vinorelbine in mouse and human EDTA plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.

C. Damen, J. Schellens, H. Rosing, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications.

A. Breckenridge, J. Schellens, H. Leufkens, 2015, The oncologist.

Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite β‑decitabine in human plasma, whole blood and urine.

J. Schellens, H. Rosing, J. Beijnen, 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma.

J. Schellens, J. Beijnen, A. Schinkel, 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study

J. Schellens, J. V. van Sandick, A. Aalbers, 2017, JMIR research protocols.

Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors

J. Schellens, L. Siu, A. Hansen, 2015, Clinical Cancer Research.

A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers

J. Schellens, A. Hansen, M. Demario, 2014, Clinical Cancer Research.

Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine

J. Schellens, H. Rosing, J. Beijnen, 2011, Cancer Chemotherapy and Pharmacology.

Long-term platinum retention after treatment with cisplatin and oxaliplatin

J. Schellens, J. Beijnen, A. Huitema, 2008, BMC clinical pharmacology.

Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours

J. Schellens, H. Rosing, J. Beijnen, 2007, Cancer Chemotherapy and Pharmacology.

Development and validation of a quantitative method for thymidine phosphorylase activity in peripheral blood mononuclear cells

J. Schellens, J. Beijnen, Anna Tzani, 2018, Nucleosides, nucleotides & nucleic acids.

Corrigendum to “Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy”

J. Schellens, J. Beijnen, A. Huitema, 2015, BioMed research international.

BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers.

J. Desai, J. Schellens, J. Tabernero, 2018 .

Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells.

J. Schellens, J. Beijnen, D. Pluim, 2015, Bioanalysis.

Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel.

J. Schellens, J. Beijnen, A. Huitema, 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.

J. Ware, J. Spoerke, J. Schellens, 2017, The oncologist.

A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors

R. Plummer, M. Ranson, J. Schellens, 2016, Investigational New Drugs.

Thermal stability study of crystalline and novel spray‐dried amorphous nilotinib hydrochloride

J. Schellens, J. Beijnen, H. Vromans, 2018, Journal of pharmaceutical and biomedical analysis.

First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers

A. Tutt, J. Carmichael, J. Schellens, 2007 .

Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.

J. Schellens, H. Rosing, J. Beijnen, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis

J. Schellens, H. Rosing, J. Beijnen, 2019, CPT: pharmacometrics & systems pharmacology.

Effectiveness and safety of reduced‐dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis

J. Schellens, J. Beijnen, A. de Boer, 2019, International journal of cancer.

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? - Authors' reply.

J. Schellens, H. Guchelaar, R. Mathijssen, 2019, The Lancet. Oncology.

Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine.

J. Schellens, H. Boot, M. Deenen, 2010, Annals of internal medicine.

Pharmacodynamic assay of thymidylate synthase activity in peripheral blood mononuclear cells

J. Schellens, J. Beijnen, D. Pluim, 2013, Analytical and Bioanalytical Chemistry.

Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors

J. Schellens, J. Beijnen, L. Weiner, 2010, European Journal of Drug Metabolism and Pharmacokinetics.

Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer.

J. Schellens, H. Rosing, J. Beijnen, 1998, Anti-cancer drugs.

Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma.

J. Schellens, J. Beijnen, A. Schinkel, 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.

Henk-Jan Guchelaar, Jesse J Swen, J. Schellens, 2016, European journal of cancer.

[Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].

J. Schellens, J. Beijnen, M. Deenen, 2012, Nederlands tijdschrift voor geneeskunde.

Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy.

J. Schellens, J. Beijnen, J. Severens, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial

W. Dreschler, M. Hauptmann, J. Schellens, 2021, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.

J. Schellens, J. Beijnen, A. Huitema, 2013, British journal of clinical pharmacology.

Neutropenia and docetaxel exposure in metastatic castration‐resistant prostate cancer patients: A meta‐analysis and evaluation of a clinical cohort

J. Schellens, J. Beijnen, A. Huitema, 2019, Cancer medicine.

Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma.

J. Schellens, J. Beijnen, J. Molenaar, 2014, Journal of pharmaceutical and biomedical analysis.

Rapid Detection of the DPYD IVS14+1G>A Mutation for Screening Patients to Prevent Fluorouracil-Related Toxicity

J. Schellens, J. Beijnen, A. Cats, 2012, Molecular Diagnosis & Therapy.

Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry.

J. Schellens, J. Beijnen, A. Schinkel, 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.

J. Schellens, J. Beijnen, A. Bergamo, 2012, Journal of inorganic biochemistry.

Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2005, Biomedical chromatography : BMC.

PERFORMANCE OF THE ANALYTICAL ASSAYS OF PACLITAXEL, DOCETAXEL, AND CYCLOSPORIN A IN A ROUTINE HOSPITAL LABORATORY SETTING

J. Schellens, H. Rosing, J. Beijnen, 2001 .

Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion

S. Rodenhuis, J. Schellens, H. Rosing, 2000, Cancer Chemotherapy and Pharmacology.

Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas.

M. J. van den Bent, J. Verweij, J. Schellens, 1998, European Journal of Cancer.

Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma.

J. Schellens, J. Beijnen, A. Schinkel, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

451PDPHASE I STUDY OF THE PI3Kα INHIBITOR BYL719, AS A SINGLE AGENT IN PATIENTS WITH ADVANCED SOLID TUMORS (AST).

J. Berlin, J. Baselga, H. Rugo, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of human neutrophil peptide-1, -2 and -3 as serum markers for colorectal cancer.

J. Schellens, J. Beijnen, A. Cats, 2010, Cancer biomarkers : section A of Disease markers.

Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor.

J. Schellens, M. Scheulen, V. Diéras, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined quantification of paclitaxel, docetaxel and ritonavir in human feces and urine using LC-MS/MS.

J. Schellens, H. Rosing, J. Beijnen, 2014, Biomedical chromatography : BMC.

A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

A simple and sensitive assay for the quantitative analysis of paclitaxel and metabolites in human plasma using liquid chromatography/tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2006, Biomedical chromatography : BMC.

Determination of platinum originating from carboplatin in human urine and canine excretion products by inductively coupled plasma mass spectrometry.

J. Schellens, J. Beijnen, J. D. de Vos, 2011, Journal of analytical toxicology.

Determination of platinum originating from carboplatin in canine sebum and cerumen by inductively coupled plasma mass spectrometry.

J. Schellens, J. Beijnen, J. D. de Vos, 2011, Journal of pharmaceutical and biomedical analysis.

Is fluorouracil-induced severe toxicity in DPYD*2A individuals related to sex or to treatment regimen?

J. Schellens, J. Beijnen, M. Deenen, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice

J. Schellens, J. Beijnen, A. Bergman, 2019, Drugs & Aging.

Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet

J. Schellens, J. Beijnen, A. Huitema, 2013, Drug Delivery and Translational Research.

Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples

J. Schellens, H. Rosing, J. Beijnen, 2017, Journal of pharmaceutical and biomedical analysis.

Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.

J. Schellens, H. Rosing, J. Beijnen, 2016, British journal of clinical pharmacology.

Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid

J. Schellens, M. Verheij, S. Vink, 2005, Investigational New Drugs.

Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).

J. Schellens, J. Beijnen, O. van Tellingen, 2009, Current clinical pharmacology.

Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma.

J. Schellens, A. Huitema, R. Madan, 2019, Journal of pharmaceutical and biomedical analysis.

AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study

J. Carmichael, J. Bono, J. Schellens, 2008 .

Sensitive Determination of the Carboxylate and Lactone Forms of the Novel Antitumor Drug Irinotecan and Its Active Metabolite in Plasma by HPLC

J. Schellens, H. Rosing, J. Beijnen, 1998 .

Simultaneous quantification of emtricitabine and tenofovir nucleotides in peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.

J. Schellens, J. Beijnen, K. Heinhuis, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetics and excretion of 14C–Plitidepsin in patients with advanced cancer

J. Schellens, H. Rosing, J. Beijnen, 2017, Investigational New Drugs.

Bioanalytical aspects of clinical mass balance studies in oncology.

A. C. Dubbelman, J. Schellens, H. Rosing, 2011, Bioanalysis.

A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.

J. Schellens, H. Rosing, J. Beijnen, 2009, Biomedical chromatography : BMC.

Enhanced resolution triple-quadrupole mass spectrometry for ultra-sensitive and quantitative analysis of the investigational anticancer agent EO9 (apaziquone) and its metabolite EO5a in human and dog plasma to support (pre)-clinical studies of EOquin given intravesically.

J. Schellens, H. Rosing, J. Beijnen, 2008, Rapid communications in mass spectrometry : RCM.

Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2007, Rapid communications in mass spectrometry : RCM.

Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.

J. Schellens, J. Lieverst, W. W. ten Bokkel Huinink, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care

S. Linn, J. Schellens, H. Rosing, 2014, Breast Cancer Research and Treatment.

Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure

S. Rodenhuis, J. Verweij, J. Schellens, 1996, Cancer Chemotherapy and Pharmacology.

Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice

J. Schellens, J. Beijnen, J. Garrigue, 2010, Investigational New Drugs.

Absolute quantification of farnesylated Ras levels in complex samples using liquid chromatography fractionation combined with tryptic digestion and electrospray tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2006, Analytical biochemistry.

Cancer clinical pharmacology

H. McLeod, J. Schellens, D. Newell, 2005 .

Inducing synthetic lethality using PARP inhibitors.

J. Schellens, J. Beijnen, D. Boss, 2010, Current clinical pharmacology.

Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM

Jos H. Beijnen, Ron J. Keizer, Michel van Benten, 2011, Comput. Methods Programs Biomed..

Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.

J. Schellens, J. Beijnen, F. Amant, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies

M. Ranson, J. Bono, J. Schellens, 2015, Investigational New Drugs.

Propofol extravasation in a breast cancer patient

J. Baars, J. Schellens, J. Beijnen, 2008, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real‐world cohort study: does age matter?

J. Schellens, H. Rosing, J. Beijnen, 2018, British journal of clinical pharmacology.

Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma.

J. Schellens, J. Beijnen, J. Molenaar, 2014, Journal of pharmaceutical and biomedical analysis.

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.

J. Schellens, E. Voest, H. Verheul, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors

J. Schellens, E. Voest, H. Verheul, 2010, Clinical Cancer Research.

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

J. Schellens, J. Beijnen, P. Baas, 2015, Investigational New Drugs.

Protein versus DNA as a marker for peripheral blood mononuclear cell counting

J. Schellens, H. Rosing, J. Beijnen, 2009, Analytical and bioanalytical chemistry.

Future opportunities in preventing cisplatin induced ototoxicity.

J. Schellens, J. Beijnen, A. Balm, 2006, Cancer treatment reviews.

Facile Small Scale Synthesis of Nucleoside 5′-Phosphate Mixtures

J. Schellens, H. Rosing, J. Beijnen, 2010, Nucleosides, nucleotides & nucleic acids.

Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.

J. Verweij, J. Schellens, W. Loos, 1994, Journal of the National Cancer Institute.

Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry.

Jos H Beijnen, Irene van den Broek, J. Schellens, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Liquid chromatography/tandem mass spectrometric method for the quantification of eight proteolytic fragments of ITIH4 with biomarker potential in human plasma and serum.

J. Schellens, J. Beijnen, R. Sparidans, 2008, Rapid communications in mass spectrometry : RCM.

Enzymatic digestion as a tool for the LC-MS/MS quantification of large peptides in biological matrices: measurement of chymotryptic fragments from the HIV-1 fusion inhibitor enfuvirtide and its metabolite M-20 in human plasma.

J. Schellens, J. Beijnen, R. Sparidans, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography-tandem mass spectrometry.

J. Schellens, J. Beijnen, A. Huitema, 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research.

J. Schellens, H. Rosing, J. Beijnen, 2008, Mass spectrometry reviews.

Development of a Framework for Cohort Simulation in Cost-Effectiveness Analyses Using a Multistep Ordinary Differential Equation Solver Algorithm in R

Jan A M Raaijmakers, Johan G C van Hasselt, Gerardus W J Frederix, 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

The Oral Route for the Administration of Cytotoxic Drugs: Strategies to Increase the Efficiency and Consistency of Drug Delivery

J. Schellens, J. Beijnen, O. van Tellingen, 2000, Investigational New Drugs.

Pharmacokinetics and excretion of 14C-omacetaxine in patients with advanced solid tumors

J. Schellens, H. Rosing, J. Beijnen, 2016, Investigational New Drugs.

The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography–inductively coupled plasma mass spectrometry

J. Schellens, J. Beijnen, A. Huitema, 2008, Anti-cancer drugs.

Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines

J. Schellens, J. Beijnen, D. Pluim, 2004, Cancer Chemotherapy and Pharmacology.

Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein).

J. Schellens, J. Beijnen, R. Mazzanti, 2007, The oncologist.

Herb-drug interactions in oncology: focus on mechanisms of induction.

J. Schellens, J. Beijnen, I. Meijerman, 2006, The oncologist.

Pharmaceutical development of anticancer agents derived from marine sources

J. Schellens, J. Beijnen, J. Jimeno, 2000, Anti-cancer drugs.

Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.

S. Bates, J. Schellens, D. Ross, 2003, Cancer research.

Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis.

J. Schellens, J. Beijnen, A. Huitema, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The bioanalysis of the major Echinacea purpurea constituents dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides in human plasma using LC-MS/MS.

J. Schellens, H. Rosing, J. Beijnen, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

A sensitive LC-MS/MS method for the quantitative analysis of the Echinacea purpurea constituent undeca-2-ene-8,10-diynoic acid isobutylamide in human plasma.

J. Schellens, H. Rosing, J. Beijnen, 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Mass Balance Studies, with a Focus on Anticancer Drugs

J. Schellens, J. Beijnen, J. Beumer, 2006, Clinical pharmacokinetics.

Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines.

J. Schellens, J. Beijnen, M. Deenen, 2006, Toxicology and applied pharmacology.

Design of a drug‐drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation

J. Schellens, J. Beijnen, A. Huitema, 2014, Pediatric blood & cancer.

Oral Anticancer Drugs: Mechanisms of Low Bioavailability and Strategies for Improvement

J. Schellens, J. Beijnen, B. Nuijen, 2013, Clinical Pharmacokinetics.

Severe Skin Toxicity in Pediatric Oncology Patients Treated with Voriconazole and Concomitant Methotrexate

J. Schellens, A. Huitema, A. S. Schouten-van Meeteren, 2013, Antimicrobial Agents and Chemotherapy.

Clinical pharmacology of anticancer agents in relation to formulations and administration routes.

J. Schellens, J. Beijnen, W. W. Huinink, 1999, Cancer treatment reviews.

An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons.

Jos H Beijnen, Irma Meijerman, J. Schellens, 2003, Toxicology and applied pharmacology.

Platinated DNA Adducts Enhance Poisoning of DNA Topoisomerase I by Camptothecin*

J. Schellens, M. Bjornsti, D. Pluim, 2004, Journal of Biological Chemistry.

Variability in bioavailability of small molecular tyrosine kinase inhibitors.

J. Schellens, J. Beijnen, B. Nuijen, 2015, Cancer treatment reviews.

Determination of ruthenium originating from the investigational anti-cancer drug NAMI-A in human plasma ultrafiltrate, plasma, and urine by inductively coupled plasma mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2007, Rapid communications in mass spectrometry : RCM.

Improving the solubility of nilotinib through novel spray-dried solid dispersions.

J. Schellens, J. Beijnen, B. Nuijen, 2017, International journal of pharmaceutics.

Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry

J. Schellens, H. Rosing, J. Beijnen, 2005, Analytical and bioanalytical chemistry.

Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.

J. Schellens, H. Rosing, J. Beijnen, 2011, Journal of analytical toxicology.

Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma.

J. Schellens, J. Beijnen, A. Schinkel, 2014, Journal of pharmaceutical and biomedical analysis.

PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer

S. Linn, J. Schellens, J. Beijnen, 2018, Clinical Pharmacokinetics.

Slow dissolution behaviour of amorphous capecitabine.

J. Schellens, J. Beijnen, B. Nuijen, 2013, International journal of pharmaceutics.

Liquid chromatography-tandem mass spectrometric assay for the nucleoside reverse transcriptase inhibitor emtricitabine in human plasma.

J. Schellens, J. Beijnen, J. Prins, 2007, Biomedical chromatography : BMC.

Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde.

J. Schellens, J. Beijnen, R. Sparidans, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Chronic hepatotoxicity after long-term antiretroviral treatment including nevirapine.

J. Schellens, J. Beijnen, J. Mulder, 2005, The Journal of infection.

Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of Cancer

J. Schellens, J. Beijnen, I. Meijerman, 2006, Clinical pharmacokinetics.

Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care.

J. Schellens, J. Beijnen, A. Huitema, 2016, European journal of cancer.

Optimizing drug development of anti‐cancer drugs in children using modelling and simulation

J. Schellens, J. Beijnen, A. Huitema, 2013, British journal of clinical pharmacology.

Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes.

J. Schellens, J. Beijnen, R. Sparidans, 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Development of farnesyl transferase inhibitors: a review.

J. Schellens, J. Beijnen, N. Appels, 2005, The oncologist.

In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2

Jos H. Beijnen, Alfred H. Schinkel, J. Schellens, 2007, Molecular Cancer Therapeutics.

Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

J. Schellens, H. Rosing, J. Beijnen, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses

J. Schellens, H. Rosing, J. Beijnen, 2015, Pharmacology research & perspectives.

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

Dejan Juric, Jordi Rodon, Alan Huang, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical experience with aurora kinase inhibitors: a review.

Jos H Beijnen, David S Boss, J. Schellens, 2009, The oncologist.

A Phase I, First‐in‐Human Study of GSK2849330, an Anti‐HER3 Monoclonal Antibody, in HER3‐Expressing Solid Tumors

A. Drilon, B. Hug, G. Ganji, 2021, The oncologist.

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

R. Bernards, J. Schellens, H. Rosing, 2020, British Journal of Cancer.

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential

Evert Bosdriesz, Jos H. Beijnen, Ji-Ying Song, 2018, Cell.

Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations.

T. Zander, J. Machiels, J. Schellens, 2019, JCO precision oncology.

Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA

J. Schellens, J. Beijnen, D. Pluim, 2013, Investigational New Drugs.

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.

R. Greil, P. Wen, J. Schellens, 2020, The Lancet. Oncology.

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

P. Wen, J. Schellens, J. Soria, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

Jan Lubinski, Alan Ashworth, Susan Shanley, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.

J. Schellens, H. Rosing, J. Beijnen, 2002, European journal of cancer.

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.

J. Schellens, David M. Wilson, E. Voest, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

High-performance liquid chromatography coupled with mass spectrometry for the quantitative analysis of vinca-alkaloids in biological matrices: a concise survey from the literature.

C. Damen, J. Schellens, H. Rosing, 2010, Biomedical chromatography : BMC.

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

R. Berger, M. Galsky, D. Bajorin, 2018, Cancer discovery.

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

Manuel Hidalgo, Martin Schuler, Fabrice Andre, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases

J. Schellens, J. Beijnen, K. Sikorska, 2020, Neurology.

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.

L. Chirieac, R. Plummer, M. Ranson, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment

J. Schellens, H. Rosing, J. Beijnen, 2018, Marine drugs.

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.

D. de Jong, J. Schellens, J. Beijnen, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

A. Oza, G. Shapiro, J. Schellens, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trabectedin (YondelisTM, formerly ET-743), a mass balance study in patients with advanced cancer

J. Schellens, H. Rosing, J. Beijnen, 2005, Investigational New Drugs.

Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.

J. Schellens, H. Rosing, J. Beijnen, 2005, Investigational new drugs.

ET-743. Commentaries

D. Figgitt, J. Schellens, J. Beijnen, 2002 .

Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.

J. Schellens, H. Rosing, J. Beijnen, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

AKT Inhibition in Solid Tumors With AKT1 Mutations.

B. Taylor, M. Berger, S. Chandarlapaty, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors

J. Schellens, J. Beijnen, K. Heinhuis, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacogenetic Screening of the Gene Deletion and Duplications of CYP2D6

J. Schellens, J. Beijnen, L. Sanderson, 2007, Drug metabolism reviews.

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer

J. Baselga, M. Ranson, J. Schellens, 2018, Cancer Chemotherapy and Pharmacology.

Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis

Jaana M. Hartikainen, C. Vachon, J. Olson, 2015, BMC Medicine.

Annexin A 1 expression in a pooled breast cancer series

C. Vachon, J. Olson, F. Couch, 2022 .

Application of dried blood spots combined with high-performance liquid chromatography coupled with electrospray ionisation tandem mass spectrometry for simultaneous quantification of vincristine and actinomycin-D

C. Damen, J. Schellens, H. Rosing, 2009, Analytical and bioanalytical chemistry.

Concise drug review: azacitidine and decitabine.

Jos H Beijnen, J. Schellens, J. Beijnen, 2013, The oncologist.

A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK

J. Schellens, U. Banerji, P. Lawrence, 2018, Cancer Chemotherapy and Pharmacology.

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

J. Barrett, J. Schellens, P. Elvin, 2017, Clinical Cancer Research.

Abstract LB-66: Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors .

M. Ranson, J. Schellens, K. Tamura, 2013 .

Results of two Phase 1 multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors.

M. Ranson, J. Schellens, K. Tamura, 2013 .

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.

J. Schellens, A. Le Cesne, M. D. de Jonge, 2017, European journal of cancer.

Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first‐line platinum‐gemcitabine chemotherapy

E. Smit, J. Schellens, J. Beijnen, 2012, Cancer.

Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.

J. Schellens, J. Beijnen, M. Deenen, 2011, The oncologist.

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity

J. Schellens, H. Rosing, J. Beijnen, 2017, British Journal of Cancer.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Julia M. Barbarino, Ursula Amstutz, T. Klein, 2018, Clinical pharmacology and therapeutics.

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.

J. Sanderson, U. Amstutz, I. Tomlinson, 2015, The Lancet. Oncology.

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer

J. Schellens, J. Beijnen, G. Sonke, 2015, British Journal of Cancer.

Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer

J. Schellens, H. Rosing, J. Beijnen, 2017, Investigational New Drugs.

Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression

J. Schellens, J. Beijnen, A. Zandvliet, 2009, Journal of Pharmacokinetics and Pharmacodynamics.

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023

J. Schellens, H. Rosing, J. Beijnen, 2013, Cancer Chemotherapy and Pharmacology.

Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasartrade mark, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2005, Rapid communications in mass spectrometry : RCM.

Validated assay for the simultaneous quantification of total vincristine and actinomycin-D concentrations in human EDTA plasma and of vincristine concentrations in human plasma ultrafiltrate by high-performance liquid chromatography coupled with tandem mass spectrometry.

C. Damen, J. Schellens, H. Rosing, 2009, Rapid communications in mass spectrometry : RCM.

Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods

S. Rodenhuis, J. Schellens, J. Beijnen, 2000, Clinical pharmacology and therapeutics.

Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients

J. Schellens, J. Beijnen, M. Campone, 2007, Cancer Chemotherapy and Pharmacology.

A Phase I and Pharmacological Study of the Platinum Polymer AP5280 Given as an Intravenous Infusion Once Every 3 Weeks in Patients with Solid Tumors

J. Schellens, J. Beijnen, S. Howell, 2004, Clinical Cancer Research.

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic malignant melanoma.

J. Verweij, J. Schellens, C. Vecht, 1996, European journal of cancer.

Modulation of Oral Drug Bioavailability: From Preclinical Mechanism to Therapeutic Application

J. Schellens, J. Beijnen, P. Breedveld, 2005, Cancer investigation.

Moving towards dose individualization of tyrosine kinase inhibitors.

J. Schellens, R. Mathijssen, H. Gurney, 2011, Cancer treatment reviews.

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.

J. Verweij, J. Schellens, P. Schmitz, 1996, British Journal of Cancer.

Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma.

Jos H Beijnen, David S Boss, C. Damen, 2009, Analytical biochemistry.

Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin

J. Schellens, H. Rosing, J. Beijnen, 2008, Analytical and bioanalytical chemistry.

Liquid chromatography-tandem mass spectrometric assays for salinomycin in mouse plasma, liver, brain and small intestinal contents and in OptiMEM cell culture medium.

J. Schellens, J. Beijnen, J. S. Lagas, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Persistent neuropathy after treatment with cisplatin and oxaliplatin

J. Schellens, J. Beijnen, A. Huitema, 2009, Acta oncologica.

Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 study.

J. Schellens, H. Chung, A. Marabelle, 2017 .

Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients

J. Schellens, H. Rosing, J. Beijnen, 2022, Drug Metabolism and Disposition.

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.

R. Bernards, J. Engelman, A. Bardelli, 2016, Cancer research.

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

J. Larkin, M. Venturi, J. Schellens, 2014, Clinical Cancer Research.

BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

J. Millholland, C. Atreya, E. Van Cutsem, 2020, Clinical Cancer Research.

Safety, pharmacokinetics, and preliminary activity of the alpha-specific PI3K inhibitor BYL719: Results from the first-in-human study.

J. Berlin, J. Baselga, D. Juric, 2013 .

366 Phase I Dose-escalation Study of the Oral Dual MTOR/PI3K Inhibitor BEZ235, Solid Dispersion System (SDS) Sachet Formulation, in Patients with Advanced Solid Tumors

J. Baselga, J. Schellens, M. Schuler, 2012 .

Pharmacokinetically Guided Administration of Chemotherapeutic Agents

J. Schellens, J. Beijnen, R. Mathôt, 2000, Clinical pharmacokinetics.

Carboplatin Dosage Formulae Can Generate Inaccurate Predictions of Carboplatin Exposure in Carboplatin/Paclitaxel Combination Regimens

G. Giaccone, J. Schellens, J. Beijnen, 1998, Clinical drug investigation.

Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.

J. Schellens, J. Beijnen, M. Deenen, 2011, The oncologist.

Ras biochemistry and farnesyl transferase inhibitors: a literature survey

J. Schellens, J. Beijnen, G. Klerk, 2001, Anti-cancer drugs.

Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function.

J. Schellens, J. Beijnen, W. S. Siegel-Lakhai, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Photodynamic therapy in oncology.

Paul Baas, F. Stewart, J. Schellens, 2006, The oncologist.

Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors

E. Raymond, J. Schellens, A. Italiano, 2020, Targeted Oncology.

Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies.

Jos H Beijnen, C. Damen, J. Schellens, 2009, Human antibodies.

Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

J. Schellens, J. Beijnen, E. Voest, 2011, Clinical Cancer Research.

A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies

J. Schellens, E. Voest, G. Cirkel, 2016, Investigational New Drugs.

Improving colorectal cancer management: the potential of proteomics.

J. Schellens, J. Beijnen, A. Cats, 2008, Biomarkers in medicine.

Treatment Individualization in Colorectal Cancer

Jos H. Beijnen, René Bernards, R. Bernards, 2015, Current Colorectal Cancer Reports.

11LBA Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer

S. Jaeger, J. Schellens, H. Lenz, 2014 .

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

J. Desai, E. Van Cutsem, J. Schellens, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei

J. Schellens, D. Pluim, J. Thomale, 2006, Nucleic acids research.

Fixed Dosing of Monoclonal Antibodies in Oncology

J. Schellens, J. Beijnen, E. Voest, 2017, The oncologist.

“Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183”

J. Schellens, J. Beijnen, D. Pluim, 2014, Investigational New Drugs.

Transport of Topoisomerase I Inhibitors by the Breast Cancer Resistance Protein: Potential Clinical Implications

J. Schellens, J. Beijnen, A. Schinkel, 2000, Annals of the New York Academy of Sciences.

Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

F H Hausheer, J. Schellens, J. Beijnen, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study

Ping Yang, J. Schellens, K. Tamura, 2020, Cancer.

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib

J. Schellens, J. Beijnen, O. Tellingen, 2009, Investigational New Drugs.

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients

J. Schellens, H. Rosing, J. Beijnen, 2001, British Journal of Cancer.

Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.

J. Schellens, H. Rosing, J. Beijnen, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

The Effect of Low pH on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport of Methotrexate, 7-Hydroxymethotrexate, Methotrexate Diglutamate, Folic Acid, Mitoxantrone, Topotecan, and Resveratrol in In Vitro Drug Transport Models

Jos H. Beijnen, Piet Borst, Gerrit Jansen, 2007, Molecular Pharmacology.

Breast Cancer Resistance Protein (Bcrp1/Abcg2) Limits Net Intestinal Uptake of Quercetin in Rats by Facilitating Apical Efflux of Glucuronides

J. Schellens, I. Arts, P. Hollman, 2005, Molecular Pharmacology.

Expression of the breast cancer resistance protein in breast cancer.

M. J. van de Vijver, P. Kristel, J. Schellens, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Modulation of oral bioavailability of anticancer drugs: from mouse to man.

J. Schellens, J. Beijnen, O. van Tellingen, 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies.

J. Schellens, J. Beijnen, A. de Boer, 2017, The oncologist.

Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective.

S. Linn, J. Schellens, J. Beijnen, 2015, Clinical breast cancer.

Progress in the Development of Alternative Pharmaceutical Formulations of Taxanes

J. Schellens, J. Beijnen, B. Nuijen, 2001, Investigational New Drugs.

Pharmacogenetic Screening for Polymorphisms in Drug-Metabolizing Enzymes and Drug Transporters in a Dutch Population

J. Schellens, J. Beijnen, I. Meijerman, 2012, Molecular Diagnosis & Therapy.

Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel

W. M. Smit, J. Schellens, J. Beijnen, 2006, Clinical Cancer Research.

Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.

J. Schellens, J. Beijnen, A. Goey, 2013, Cancer treatment reviews.

Phase I study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced solid tumors.

A. Jager, J. Bono, J. Schellens, 2013 .

Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue.

J. Schellens, H. Rosing, J. Beijnen, 2012, Bioanalysis.

A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling

J. Schellens, J. Beijnen, H. J. van den Bongard, 2002, Cancer Chemotherapy and Pharmacology.

Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction

J. Schellens, J. Beijnen, H. Boot, 2015, Cancer Chemotherapy and Pharmacology.

Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.

J. Schellens, J. Beijnen, H. Boot, 2013, International journal of radiation oncology, biology, physics.

Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model

J. Schellens, A. Eggermont, W. Loos, 1996, Journal of Cancer Research and Clinical Oncology.

Oral Delivery of Taxanes

J. Schellens, J. Beijnen, M. Malingré, 2001, Investigational New Drugs.

Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study

A. Zwinderman, Y. Daali, J. Schellens, 2014, Clinical Pharmacokinetics.

Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets

J. Schellens, J. Beijnen, A. Huitema, 2014, Clinical Pharmacokinetics.

A first-in-human study of the oral selective androgen receptor down-regulating drug (SARD) AZD3514 in patients with castration-resistant prostate cancer (CRPC).

M. Ranson, J. Bono, J. Schellens, 2013 .

Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype.

J. Lubiński, J. Carmichael, J. Schellens, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil.

J. Schellens, J. Beijnen, J H Beijnen, 1999, Pharmacological research.

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

J. Schellens, J. Beijnen, M. Deenen, 2011, The oncologist.

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.

J. Schellens, J. Beijnen, D. de Jong, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

P. Jänne, J. Engelman, J. Schellens, 2011, Clinical Cancer Research.

Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer.

J. Schellens, H. Rosing, J. Beijnen, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors.

J. Schellens, J. Beijnen, I. Meijerman, 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours

J. Schellens, M. D. de Jonge, M. Langenberg, 2018, British Journal of Cancer.

Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities.

J. Schellens, J. Beijnen, S. Leijen, 2013, Cancer treatment reviews.

Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?

J. Schellens, J. Beijnen, J. Haanen, 2013, Cancer treatment reviews.

Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine.

J. Schellens, H. Rosing, J. Beijnen, 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

First-in-human study of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-00299804, a small molecule irreversible panHER inhibitor in patients with advanced cancer

J. Schellens, D. Camidge, C. Britten, 2007 .

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours

S. Sleijfer, J. Schellens, J. Beijnen, 2014, British Journal of Cancer.

The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand–foot syndrome

J. Schellens, J. Beijnen, C. Blank, 2013, European Journal of Clinical Pharmacology.

Quantification of Sunitinib and N-Desethyl Sunitinib in Human EDTA Plasma by Liquid Chromatography Coupled With Electrospray Ionization Tandem Mass Spectrometry: Validation and Application in Routine Therapeutic Drug Monitoring

J. Schellens, H. Rosing, J. Beijnen, 2013, Therapeutic drug monitoring.

Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer.

J. Schellens, J. Beijnen, I. Meijerman, 2008, Cancer treatment reviews.

A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel

J. Schellens, J. Beijnen, L. V. van Warmerdam, 1999, Journal of Cancer Research and Clinical Oncology.

Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer

J. Schellens, M. Verheij, D. Pluim, 2020, Clinical Cancer Research.

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

J. Schellens, H. Verheul, A. Awada, 2020, British Journal of Cancer.

Phase I pharmacological study of continuous chronomodulated capecitabine treatment

J. Schellens, H. Rosing, J. Beijnen, 2020, Pharmaceutical Research.

Vorinostat in patients with resistant BRAFV600E mutated advanced melanoma: a proof of concept study.

R. Bernards, J. Schellens, H. Rosing, 2020, Future oncology.

Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine

J. Schellens, R. Mathijssen, T. van Gelder, 2019, Therapeutic advances in medical oncology.

Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment

Myung Ah Lee, J. Blay, A. Ravaud, 2020, British journal of clinical pharmacology.

Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP

J. Schellens, J. Beijnen, Jin Zhao, 2012, Investigational New Drugs.

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma.

J. Schellens, H. Rosing, J. Beijnen, 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001).

J. Schellens, J. Beijnen, A. Huitema, 2011, International journal of pharmaceutics.

Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor

J. H. Beijnen, J. Schellens, J. Beijnen, 2009, Cancer Chemotherapy and Pharmacology.

Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer

R. Bernards, J. Schellens, H. Rosing, 2020, Cancer Chemotherapy and Pharmacology.

How Much Longer Will We Put Up With $100,000 Cancer Drugs?

Paul Workman, René Bernards, R. Bernards, 2017, Cell.

The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.

J. Schellens, B. Jonsson, S. Marchetti, 2013, European journal of cancer.

Allometric scaling of pegylated liposomal anticancer drugs

J. Schellens, J. Beijnen, H. Clewell, 2011, Journal of Pharmacokinetics and Pharmacodynamics.

Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.

W. M. Smit, E. D. de Vries, J. Schellens, 2016, JAMA oncology.

Milk Thistle’s Active Components Silybin and Isosilybin: Novel Inhibitors of PXR-Mediated CYP3A4 Induction

J. Schellens, J. Beijnen, I. Meijerman, 2013, Drug Metabolism and Disposition.

Scientific Spring Meeting Friday March 20 , 2015 Dutch Society for Clinical Pharmacology and Biopharmacy Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie

Hilde, Niels, J. Schellens, 2015 .

Impact of age on exposure to oral antiandrogen therapies in clinical practice

J. Schellens, H. Rosing, J. Beijnen, 2018, Prostate Cancer and Prostatic Diseases.

Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.

B. Reigner, J. Verweij, J. Schellens, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The biological and clinical role of drug transporters at the intestinal barrier.

Jos H Beijnen, J. Schellens, J. Beijnen, 2009, Cancer treatment reviews.

Carcinogen and Anticancer Drug Transport by Mrp2 in Vivo: Studies Using Mrp2 (Abcc2) Knockout Mice

J. Schellens, H. Rosing, J. Beijnen, 2006, Journal of Pharmacology and Experimental Therapeutics.

Evidence for Two Interacting Ligand Binding Sites in Human Multidrug Resistance Protein 2 (ATP Binding Cassette C2)*

J. Schellens, P. Wielinga, G. Reid, 2003, Journal of Biological Chemistry.

Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography-tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2016, Journal of pharmaceutical and biomedical analysis.

Dosing oxaliplatin in a haemodialysis patient with metastatic rectum cancer monitored by free platinum concentrations

J. Schellens, A. Huitema, A. Imholz, 2018, Journal of clinical pharmacy and therapeutics.

Determination of 9-nitrocamptothecin and its metabolite 9-aminocamptothecin in human plasma using high-performance liquid chromatography with ultraviolet and fluorescence detection.

J. Schellens, H. Rosing, J. Beijnen, 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

The use of combinations of monoclonal antibodies in clinical oncology.

J. Schellens, J. Beijnen, A. Huitema, 2015, Cancer treatment reviews.

Pharmacokinetics and excretion of 14C-lenvatinib in patients with advanced solid tumors or lymphomas

A. C. Dubbelman, J. Schellens, H. Rosing, 2015, Investigational New Drugs.

Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial

E. Raymond, J. Schellens, A. Italiano, 2020, Targeted Oncology.

Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma.

J. Schellens, J. Beijnen, A. Schinkel, 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Circulating tumor cell detection in advanced non-small cell lung cancer patients by multi-marker QPCR analysis.

J. Schellens, E. Voest, A. Bosma, 2012, Lung cancer.

PI3K Kinase Inhibitor GSK2126458 (GSK458): Clinical Activity in Select Patient (PT) Populations Defined by Predictive Markers (STUDY P3K112826)

N. Agarwal, J. Schellens, A. Tan, 2012 .

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

J. Schellens, M. Nicolson, S. Leijen, 2011, Cancer Chemotherapy and Pharmacology.

Bayesian Pharmacokinetically Guided Dosing of Paclitaxel in Patients with Non-Small Cell Lung Cancer

J. Schellens, H. Rosing, J. Beijnen, 2004, Clinical Cancer Research.

Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).

J. Schellens, J. Beijnen, W. S. Siegel-Lakhai, 2005, The oncologist.

Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer.

J. Schellens, J. V. van Sandick, H. Boot, 2015, Critical reviews in oncology/hematology.

UvA-DARE ( Digital Academic Repository ) HIPEC treatment of peritoneal carcinomatosis in colorectal and gastric cancer

J. Schellens, H. Boot, C. Knibbe, 2015 .

Clinical Pharmacokinetics and Pharmacodynamics of Ifosfamide and its Metabolites

H. Groen, H. Keizer, J. Schellens, 2001, Clinical Pharmacokinetics.

Clinical proteomics in breast cancer: a review

Jos H. Beijnen, Marie-Christine W. Gast, J. Schellens, 2009, Breast Cancer Research and Treatment.

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants

A. V. van Kuilenburg, J. Schellens, H. Guchelaar, 2018, Genes.

Abstract CT073: Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies

D. Planchard, J. Schellens, W. Miller, 2019, Clinical Trials.

Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study

J. Schellens, H. Rosing, J. Beijnen, 2012, Cancer Chemotherapy and Pharmacology.

The PARP inhibitor olaparib (LynparzaTM) has shown an acceptable toxicity profile as monotherapy at doses up to 400 mg twice daily with encouraging signs of anti-tumor activity, especially in BRCA mutation carriers. Based on its mode of action, olaparib

J. Bono, J. Schellens, H. Arkenau, 2020 .

Lapatinib for advanced or metastatic breast cancer.

Henk-Jan Guchelaar, Jos H Beijnen, J. Schellens, 2012, The oncologist.

Phase I trial to determine the safety and tolerability of GW572016 in combination with oxaliplatin (OX)/5-fluorouracil (5-FU)/leucovorin (LV) [FOLFOX4] in patients with solid tumors.

D. Richel, J. Schellens, J. Beijnen, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC).

P. Wen, J. Schellens, J. Soria, 2017 .

Pharmacodynamic biomarkers in model-based drug development in oncology.

J. Schellens, J. Beijnen, A. Huitema, 2011, Current clinical pharmacology.

Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma

J. Schellens, M. Egorin, D. Pluim, 2004, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin

J. Schellens, J. Beijnen, G. Groenewegen, 2002, Cancer Chemotherapy and Pharmacology.

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.

D. Planchard, J. Schellens, W. Miller, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pharmacokinetics of the multidrug-resistance-converting drug dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of tumor-bearing Wag / Rij rats

J. Verweij, A. Eggermont, J. Schellens, 1997, Cancer Chemotherapy and Pharmacology.

Simple high-performance liquid chromatographic assay for melphalan in perfusate, rat liver and tumour tissue.

J. Schellens, J. Beijnen, G. Mulder, 2003, Biomedical chromatography : BMC.

Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine.

A. C. Dubbelman, J. Schellens, H. Rosing, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma.

J. Schellens, J. Beijnen, L. V. Valkenburg-van Iersel, 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor

H. Bartelink, F. Hoebers, L. Stalpers, 2007, Cancer Chemotherapy and Pharmacology.

Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule

J. Schellens, H. Rosing, J. Beijnen, 2002, Cancer Chemotherapy and Pharmacology.

Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma

S. Rodenhuis, H. Keizer, J. Schellens, 2001, European Journal of Clinical Pharmacology.

A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)

J. Verweij, J. Schellens, D. V. Von Hoff, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors

J. Schellens, H. Rosing, J. Beijnen, 2009, Clinical Cancer Research.

Oral topotecan: bioavailability and effect of food co-administration

J. Schellens, H. Rosing, J. Beijnen, 1999, British Journal of Cancer.

No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan

P. Opolon, J. Schellens, G. Vassal, 2004, British Journal of Cancer.

INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors.

J. Schellens, M. Millward, M. Maio, 2017 .

ENGAGE-1: A first in human study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors.

F. Hodi, J. Schellens, D. Kaufman, 2016 .

Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.

J. Verweij, J. Schellens, G. Stoter, 1994, British Journal of Cancer.

The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials

J. Schellens, S. Marchetti, J H M Schellens, 2007, British Journal of Cancer.

Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol®) and carboplatin in non-small cell lung cancer patients

G. Giaccone, J. Schellens, J. Beijnen, 2000, Anti-cancer drugs.

EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors.

J. Westerga, J. Schellens, J. Beijnen, 2016, Neuro-oncology.

EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid

J. Schellens, J. Beijnen, D. Pluim, 2018, Journal of Neuro-Oncology.

Bayesian pharmacokinetics of lithium after an acute self-intoxication and subsequent haemodialysis: a case report.

J. Schellens, J. Beijnen, R. Mathôt, 2002, Pharmacology & toxicology.

Serum β-HCG and CA-125 as Tumor Markers in a Patient with Osteosarcoma: Case Report

D. de Jong, J. Wanders, J. Schellens, 2011 .

Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate.

S. Krähenbühl, J. Schellens, A. Huitema, 2012, British journal of clinical pharmacology.

Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.

H. Keizer, J. Schellens, J. Beijnen, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Individualised Cancer Chemotherapy: Strategies and Performance of Prospective Studies on Therapeutic Drug Monitoring with Dose Adaptation

Jos H. Beijnen, Alwin D. R. Huitema, S. Rodenhuis, 2005, Clinical pharmacokinetics.

Acute poisoning after oral intake of a toluene-containing paint thinner

J. Schellens, J. Beijnen, M. Tibben, 2002, European Journal of Pediatrics.

Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.

J. Schellens, H. Guchelaar, H. Gelderblom, 2015, Pharmacogenomics.

Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.

J. Schellens, J. Beijnen, J. Schornagel, 2006, British journal of clinical pharmacology.

Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy.

J. Schellens, J. Beijnen, S. Veltkamp, 2008, The oncologist.

Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection

J. Schellens, H. Rosing, J. Beijnen, 2016, Antimicrobial Agents and Chemotherapy.

Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes

J. Verweij, J. Schellens, W. Loos, 1996, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours

J. Schellens, H. Rosing, J. Beijnen, 1999, Cancer Chemotherapy and Pharmacology.

Cyclosporine-Induced Anaphylaxis

J. Schellens, J. Beijnen, R. A. Kuiper, 2000, The Annals of pharmacotherapy.

Pharmacokinetics and Excretion of 14C-Bendamustine in Patients with Relapsed or Refractory Malignancy

A. C. Dubbelman, J. Schellens, H. Rosing, 2013, Drugs in R&D.

Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer

J. Schellens, J. Beijnen, B. Thürlimann, 2016, Cancers.

In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide.

J. Schellens, J. Beijnen, J. D. J. van den Berg, 1998, Cancer treatment reviews.

Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9

J. Schellens, 2001, Anti-cancer drugs.

Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors.

J. Verweij, J. Schellens, G. Stoter, 1999, Anti-cancer drugs.

Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel

J. Schellens, H. Rosing, J. Beijnen, 2001, Anti-cancer drugs.

Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration

J. Schellens, H. Rosing, J. Beijnen, 2000, Anti-cancer drugs.

A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application

J. Schellens, H. Rosing, J. Beijnen, 2006, Cancer Chemotherapy and Pharmacology.

The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel

J. Schellens, H. Rosing, J. Beijnen, 2001, Anti-cancer drugs.

Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes.

J. Schellens, J. Severens, A. Hövels, 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Metabolite Profiling of Bendamustine in Urine of Cancer Patients after Administration of [14C]Bendamustine

A. C. Dubbelman, J. Schellens, H. Rosing, 2012, Drug Metabolism and Disposition.

Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trial

F. Cavalli, S. Krähenbühl, M. Reni, 2010, British Journal of Cancer.

Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study

J. Schellens, J. Beijnen, K. Sikorska, 2016, Investigational New Drugs.

Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer

W. M. Smit, J. Schellens, H. Rosing, 2015, Investigational New Drugs.

Baclofen overdose treated with continuous venovenous hemofiltration

J. Schellens, J. Beijnen, A. Huitema, 2015, European Journal of Clinical Pharmacology.

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C β-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer

J. Schellens, J. Beijnen, E. Voest, 2007, Clinical Cancer Research.

Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer

Marie-Christine W. Gast, P. Span, J. Schellens, 2011, Journal of Cancer Research and Clinical Oncology.

Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients

Marie-Christine W. Gast, S. Rodenhuis, P. Span, 2008, BMC Cancer.

The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients

J. Schellens, H. Rosing, J. Beijnen, 2016, Journal of clinical pharmacology.

Influence of variations in sample handling on SELDI‐TOF MS serum protein profiles for colorectal cancer

J. Schellens, J. Beijnen, A. Cats, 2008, Proteomics. Clinical applications.

Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry.

Jos H Beijnen, J. Schellens, J. Beijnen, 2006, World journal of gastroenterology.

Validation of a quantitative assay for human neutrophil peptide-1, -2, and -3 in human plasma and serum by liquid chromatography coupled to tandem mass spectrometry.

J. Schellens, J. Beijnen, R. Sparidans, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.

J. Schellens, H. Rosing, J. Beijnen, 2006, Journal of mass spectrometry : JMS.

Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models.

S. Sleijfer, J. Schellens, J. Beijnen, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Part 1: background, methodology, and clinical adoption of pharmacogenetics.

J. Schellens, J. Beijnen, M. Deenen, 2011, The oncologist.

Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations

J. Schellens, J. Beijnen, E. Voest, 2007, Laboratory Investigation.

Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients.

S. Sleijfer, D. Richel, J. Schellens, 2012, European urology.

Identification of two new serum protein profiles for renal cell carcinoma.

J. Schellens, J. Beijnen, E. Voest, 2009, Oncology reports.

Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS)

Marie-Christine W. Gast, E. Rutgers, J. Schellens, 2009, Clinical chemistry and laboratory medicine.

Importance of highly selective LC–MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen

S. Linn, J. Schellens, H. Rosing, 2012, Breast Cancer Research and Treatment.

Selection of oncology medicines in low- and middle-income countries.

J. Schellens, H. Leufkens, A. de Boer, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Development and validation of a high‐performance liquid chromatography‐tandem mass spectrometry assay for the quantification of Dexamphetamine in human plasma

J. Schellens, H. Rosing, J. Beijnen, 2018, Journal of pharmaceutical and biomedical analysis.

Severe Cannabinoid Intoxication in A Patient with Non-Small-Cell Lung Cancer

J. Schellens, J. Beijnen, A. Huitema, 2012, Journal of palliative care.

Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium.

P. Neven, J. Schellens, J. Severens, 2014, European journal of cancer care.

Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology

J. Schellens, J. Beijnen, A. Huitema, 2018, Clinical Pharmacokinetics.

Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers

J. Schellens, J. Beijnen, R. Sparidans, 2010, Clinical Proteomics.

Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling.

Marie-Christine W. Gast, J. Westerga, J. Schellens, 2009, The International journal of biological markers.

Detection of Breast Cancer by Surface-enhanced Laser Desorption/Ionization Time-of-flight Mass Spectrometry Tissue and Serum Protein Profiling

Marie-Christine W. Gast, J. Westerga, J. Schellens, 2009 .

Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies

J. Schellens, J. Beijnen, K. Sikorska, 2016, The Pharmacogenomics Journal.

Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care

J. Schellens, J. Beijnen, A. Huitema, 2014, Therapeutic drug monitoring.

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

S. Sleijfer, J. Schellens, C. Adessi, 2015, Clinical Cancer Research.

The absolute quantification of eight inter‐α‐trypsin inhibitor heavy chain 4 (ITIH4)‐derived peptides in serum from breast cancer patients

Marie-Christine W. Gast, J. Schellens, J. Beijnen, 2010, Proteomics. Clinical applications.

Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors

J. Schellens, J. Beijnen, A. Huitema, 2021, Cancer Chemotherapy and Pharmacology.

89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding

T. Nayak, G. V. van Dongen, O. Hoekstra, 2018, Oncotarget.

New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine

Jos H. Beijnen, Jashvant D. Unadkat, J. Schellens, 2008, Molecular Cancer Therapeutics.

Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

J. Schellens, E. Heath, P. LoRusso, 2018, Clinical Cancer Research.

Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP).

J. Tabernero, J. Schellens, M. Rodriguez-Ruiz, 2018 .

Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry.

J. Schellens, J. Beijnen, R. Sparidans, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours

J. Schellens, A. Robidoux, L. Cartee, 2014, Investigational New Drugs.

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

E. Schmidt, J. Schellens, A. Hansen, 2023, Journal for ImmunoTherapy of Cancer.

Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations

J. Verweij, J. Schellens, G. Stoter, 1996, Cancer Chemotherapy and Pharmacology.

472PPHASE 1/2A STUDY OF GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN (2B3-101) IN PATIENTS WITH BRAIN METASTASES (BM) FROM SOLID TUMORS OR RECURRENT HIGH GRADE GLIOMAS (HGG).

A. Jager, J. Schellens, C. Anders, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry

J. Schellens, J. Beijnen, A. Huitema, 2007, International archives of occupational and environmental health.

Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies

J. Schellens, J. Beijnen, B. Nuijen, 2017, Drug development and industrial pharmacy.

Utility and work productivity data for economic evaluation of breast cancer therapies in the Netherlands and Sweden.

J. Schellens, N. Quadri, A. Hövels, 2013, Clinical therapeutics.

Impact of age on exposure to oral antiandrogen therapies in clinical practice

J. Schellens, H. Rosing, J. Beijnen, 2018, Prostate Cancer and Prostatic Diseases.

The effect of Echinacea purpurea on the pharmacokinetics of docetaxel.

J. Schellens, H. Rosing, J. Beijnen, 2013, British journal of clinical pharmacology.

Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials.

Conchita Vens, Heike Peulen, J. Schellens, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug

J. Schellens, J. Beijnen, E. Brandon, 2007, Investigational New Drugs.

evelopment and validation of a high-performance liquid hromatography – tandem mass spectrometry assay quantifying laparib in human plasma

J. Schellens, H. Rosing, J. Beijnen, 2013 .

Model-based treatment optimization of a novel VEGFR inhibitor.

J. Schellens, J. Beijnen, A. Huitema, 2012, British journal of clinical pharmacology.

Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial.

O. Dalesio, J. Schellens, J. Beijnen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).

J. Desai, E. Van Cutsem, J. Schellens, 2019, Journal of Clinical Oncology.

Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first‐line treatment of patients with advanced HER2‐negative gastric cancer: A multicenter phase 2 study

J. Schellens, J. Beijnen, K. Sikorska, 2016, Cancer.

Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel.

J. Schellens, J. Beijnen, B. Nuijen, 2016, International journal of pharmaceutics.

Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.

J. Schellens, J. Beijnen, A. Huitema, 2010, British journal of clinical pharmacology.

Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet

J. Schellens, J. Beijnen, A. Huitema, 2013, Drug Delivery and Translational Research.

Analysis of 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and Its Phase I and Phase II Metabolites in Mouse Urine Using LC–UV–MS–MS

J. Schellens, H. Rosing, J. Beijnen, 2011 .

Phase I study of the selective BRAFV600inhibitor encorafenib (LGX818) combined with cetuximab and with or without the {alpha}-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer.

R. Bernards, J. Schellens, J. Tabernero, 2014 .

Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison

A. C. Dubbelman, J. Schellens, H. Rosing, 2016, Investigational New Drugs.

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents

J. Schellens, J. Beijnen, M. Karlsson, 2009, Investigational New Drugs.

Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.

J. Wanders, J. Schellens, J. Beijnen, 2008, British journal of clinical pharmacology.

A Semi-Physiological Population Pharmacokinetic Model Describing the Non-linear Disposition of Indisulam

J. Schellens, J. Beijnen, A. Zandvliet, 2006, Journal of Pharmacokinetics and Pharmacodynamics.

Population pharmacokinetics and pharmacokinetic‐pharmacodynamic relationships of the novel anticancer agent E7070 in four phase I studies

J. Wanders, E. Raymond, J. Schellens, 2002 .

Serum degradome markers for the detection of breast cancer.

Marie-Christine W. Gast, P. Peeters, J. Schellens, 2010, Journal of proteome research.

Determination of tamoxifen and endoxifen in dried blood spots using LC-MS/MS and the effect of coated DBS cards on recovery and matrix effects.

J. Schellens, H. Rosing, J. Beijnen, 2014, Bioanalysis.

Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques.

J. Schellens, H. Rosing, J. Beijnen, 2011, Journal of pharmaceutical and biomedical analysis.

Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.

R. Bernards, J. Schellens, H. Rosing, 2020, The oncologist.

Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?

J. Schellens, J. Beijnen, D. Meulendijks, 2016, Cancer treatment reviews.

Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E-mutated anaplastic thyroid cancer (ATC).

J. Schellens, A. Italiano, A. Boran, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetics and Pharmacodynamics of the Novel Marine-derived Anticancer Agent Ecteinascidin 743 in a Phase I Dose-finding Study 1

J. Schellens, H. Rosing, J. Beijnen, 2000 .

Validation of high-performance liquid chromatography-tandem mass spectrometry assays quantifying omacetaxine mepesuccinate and its 4'‑des-methyl and cephalotaxine metabolites in human plasma and urine.

J. Schellens, H. Rosing, J. Beijnen, 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography.

J. Schellens, J. Beijnen, O. Tellingen, 2007, Biomedical chromatography : BMC.

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer

A. Harris, J. Schellens, J. Beijnen, 2008, British Journal of Cancer.

Abstract CT216: Phase I dose escalating study of 2B3-101, glutathione PEGylated liposomal doxorubicin, in patients with solid tumors and brain metastases or recurrent malignant glioma

A. Jager, J. Schellens, H. Verheul, 2014 .

A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors.

J. Schellens, J. Soria, Sunil Sharma, 2016 .

Endostatin: are the 2 years up yet?

M. Ratain, J. Schellens, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.

J. Schellens, H. Rosing, J. Beijnen, 2018, Biomedical chromatography : BMC.

Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Abiraterone, Enzalutamide, and Their Major Metabolites in Human Plasma

J. Schellens, H. Rosing, J. Beijnen, 2017, Therapeutic drug monitoring.

Fast and Adequate Liquid Chromatography–Tandem Mass Spectrometric Determination of Z-endoxifen Serum Levels for Therapeutic Drug Monitoring

J. Schellens, H. Rosing, J. Beijnen, 2017, Therapeutic drug monitoring.

Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry

J. Schellens, H. Rosing, J. Beijnen, 2016, Therapeutic drug monitoring.

A drug–drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors

J. Schellens, S. Goel, U. Lassen, 2017, Cancer Chemotherapy and Pharmacology.

Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years

A. Boddy, U. Fuhr, J. Schellens, 2013, Cancer Chemotherapy and Pharmacology.

Simultaneous Quantitative Analysis of EO9 (Apaziquone) and its Conversion Products EO5a and EO9-Cl in Human and Dog Urine by High-Performance Liquid Chromatography Coupled with Electrospray Tandem Mass Spectrometry

J. Schellens, H. Rosing, J. Beijnen, 2009 .

Stability experiments in human urine with EO9 (apaziquone): a novel anticancer agent for the intravesical treatment of bladder cancer.

J. Schellens, H. Rosing, J. Beijnen, 2007, Journal of pharmaceutical and biomedical analysis.

Quantitative analysis of EO9 (apaziquone) and its metabolite EO5a in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2006, Journal of mass spectrometry : JMS.

Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.

J. Schellens, E. Voest, J. Drevs, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. EORTC Early Clinical Trials Group.

S. Aamdal, J. Verweij, J. Schellens, 1994, Oncology research.

378 A first-in-human (FIH) safety and pharmacological study of SAR405838, a novel HDM2 antagonist, in patients with solid malignancies

G. Demetri, A. Cesne, J. Schellens, 2014 .

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

C. Punt, J. Schellens, J. Beijnen, 2011, Clinical Cancer Research.

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

D. Richel, J. Schellens, J. Beijnen, 2011, Investigational New Drugs.

Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.

J. Schellens, J. Beijnen, A. Schinkel, 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14C-plitidepsin

J. Schellens, H. Rosing, J. Beijnen, 2018, Cancer Chemotherapy and Pharmacology.

Liquid chromatography‐tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine

J. Schellens, H. Rosing, J. Beijnen, 2017, Journal of pharmaceutical and biomedical analysis.

Structure elucidation of aplidine metabolites formed in vitro by human liver microsomes using triple quadrupole mass spectrometry.

A. Heck, J. Schellens, J. Beijnen, 2005, Journal of Mass Spectrometry.

Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review

J. Schellens, J. Beijnen, C. Nijenhuis, 2016, Drug metabolism reviews.

Liquid chromatographic assay for the cyclic depsipeptide aplidine, a new marine antitumor drug, in whole blood using derivatization with trans-4'-hydrazino-2-stilbazole.

J. Schellens, J. Beijnen, J. Jimeno, 2004, Biomedical chromatography : BMC.

Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors

J. Schellens, E. Voest, A. Awada, 2013, Investigational New Drugs.

Increased risk of severe fluoropyrimidine‐associated toxicity in patients carrying a G to C substitution in the first 28‐bp tandem repeat of the thymidylate synthase 2R allele

J. Schellens, J. Beijnen, D. Pluim, 2016, International journal of cancer.

Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma.

J. Schellens, H. Rosing, J. Beijnen, 2016, Journal of pharmaceutical and biomedical analysis.

The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases

J. Schellens, H. Rosing, J. Beijnen, 2018, European Journal of Clinical Pharmacology.

Effects of methimazole on the elimination of irinotecan

E. Wiemer, J. Verweij, J. Schellens, 2010, Cancer Chemotherapy and Pharmacology.

Performance of Methods for Handling Missing Categorical Covariate Data in Population Pharmacokinetic Analyses

J. Schellens, J. Beijnen, A. Zandvliet, 2012, The AAPS Journal.

Optimal management of emergent hypertension during treatment with a VEGF signaling inhibitor: A randomized phase II study of cediranib

J. Schellens, E. Voest, C. Unger, 2008 .

The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand–foot syndrome

J. Schellens, J. Beijnen, C. Blank, 2013, European Journal of Clinical Pharmacology.

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

J. Schellens, R. Rueger, M. Scheulen, 2012, Clinical Cancer Research.

Cancer Therapy: Clinical Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

J. Schellens, R. Rueger, M. Scheulen, 2012 .

Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma)

J. Schellens, J. Beijnen, M. Swart, 2000, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacokinetic study of oral paclitaxel.

J. Schellens, H. Rosing, J. Beijnen, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080

Mats O. Karlsson, Jos H. Beijnen, Ron J. Keizer, 2010, Journal of Pharmacokinetics and Pharmacodynamics.

Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure

Willem Boogerd, Jos H. Beijnen, J. Schellens, 2001, Cancer Chemotherapy and Pharmacology.

Crizotinib-induced fatal fulminant liver failure.

J. Schellens, J. Beijnen, A. Huitema, 2016, Lung cancer.

Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling.

J. Schellens, H. Rosing, J. Beijnen, 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

NT-23PHASE 1/2A STUDY OF GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN (2B3-101) IN BREAST CANCER PATIENTS WITH BRAIN METASTASES (BCBM) OR RECURRENT HIGH GRADE GLIOMAS (HGG)

A. Jager, J. Schellens, C. Anders, 2014 .

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

J. Blay, P. Wen, Y. Bang, 2023, Nature Medicine.

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin

D. Lacombe, J. Verweij, J. Schellens, 2012, British Journal of Cancer.

A first-in-human trial of RG7116, a glycoengineered monoclonal antibody targeting HER3, in patients with advanced/metastatic tumors of epithelial cell origin expressing HER3 protein.

S. Sleijfer, J. Schellens, C. Adessi, 2013 .

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

S. Sleijfer, E. Felip, J. Schellens, 2017, Clinical Cancer Research.

Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination

J. Schellens, J. Beijnen, D. Pluim, 2013, Analytical and Bioanalytical Chemistry.

Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose

J. Schellens, H. Rosing, S. Marchetti, 2020, Clinical pharmacology in drug development.

Ultra‐sensitive LC–MS/MS method for the quantification of gemcitabine and its metabolite 2′,2′‐difluorodeoxyuridine in human plasma for a microdose clinical trial

J. H. Beijnen, J. Schellens, H. Rosing, 2018, Journal of pharmaceutical and biomedical analysis.

A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine

Jos H. Beijnen, J. Schellens, H. Rosing, 2016, Cancer Chemotherapy and Pharmacology.

Phase 0 (zero) clinical trials: more than zero benefit?

J. Schellens, 2009, European journal of cancer.

Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine‐associated toxicity

U. Amstutz, J. Schellens, J. Beijnen, 2016, International journal of cancer.

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

J. Schellens, M. Verheij, B. van Triest, 2019, BMC Cancer.

444OPHASE IB TRIAL TRIAL OF RG7116, A GLYCOENGINEERED MONOCLONAL ANTIBODY TARGETING HER3, IN COMBINATION WITH CETUXIMAB OR ERLOTINIB IN PATIENTS WITH ADVANCED/METASTATIC TUMORS OF EPITHELIAL CELL ORIGIN EXPRESSING HER3 PROTEIN.

S. Sleijfer, J. Schellens, C. Adessi, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium.

J. Schellens, J. Beijnen, C. Zwaan, 2017, European journal of cancer.

The effect of grape seed extract on the pharmacokinetics of dextromethorphan in healthy volunteers

J. Schellens, J. Beijnen, A. Goey, 2013, European Journal of Clinical Pharmacology.

A Phase II Study of Patupilone (EPO906) in Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer

W. M. Smit, A. Oza, H. Hirte, 2012 .

Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer.

R. Bernards, J. Schellens, H. Rosing, 2020 .

Drug Formulations: How these Affects Anticancer Drug

J. Schellens, J. Beijnen, B. Nuijen, 2014 .

The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.

J. Bergh, J. Schellens, D. Melchiorri, 2014, The oncologist.

P12 SELDI-TOF MS serum protein profiling predicts poor prognosis renal cancer patients

J. Schellens, J. Beijnen, E. Voest, 2007 .

Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel

J. Schellens, J. Beijnen, W. W. ten Bokkel Huinink, 2001, Anti-cancer drugs.

Incidence of Hematologic Toxicity in Older Adults Treated with Gemcitabine or a Gemcitabine-Containing Regimen in Routine Clinical Practice: A Multicenter Retrospective Cohort Study

J. Schellens, J. Beijnen, A. Huitema, 2014, Drugs & Aging.

Model-Based Evaluation and Optimization of Cardiac Monitoring Protocols for Adjuvant Treatment of Breast Cancer with Trastuzumab

J. Schellens, J. Beijnen, A. Huitema, 2012, Pharmaceutical Research.

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen

J. Schellens, H. Rosing, J. Beijnen, 2018, Breast Cancer Research and Treatment.

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose

J. Schellens, J. Beijnen, A. Huitema, 2018, Investigational New Drugs.

Capecitabine

J. Schellens, 2022, Reactions Weekly.

Thermal study of pazopanib hydrochloride

J. Schellens, J. Beijnen, B. Nuijen, 2017, Journal of Thermal Analysis and Calorimetry.

Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy

J. Schellens, J. Beijnen, A. Huitema, 2014, BioMed research international.

Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular‐signal‐regulated kinase and DNA in circulating tumor cells

J. Schellens, J. Beijnen, D. Pluim, 2012, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction.

J. Schellens, J. Beijnen, A. Schinkel, 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC).

C. Atreya, J. Schellens, J. Tabernero, 2015 .

Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice.

Francesco Trotta, J. Schellens, H. Leufkens, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The in‐vitro effect of complementary and alternative medicines on cytochrome P450 2C9 activity

J. Schellens, J. Beijnen, A. Goey, 2014, The Journal of pharmacy and pharmacology.

Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen

S. Linn, J. Schellens, H. Rosing, 2014, Breast Cancer Research and Treatment.

Performance of Methods for Handling Missing Categorical Covariate Data in Population Pharmacokinetic Analyses

J. Schellens, J. Beijnen, A. Zandvliet, 2012, The AAPS Journal.

517PBEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC)

J. Desai, J. Schellens, A. Grothey, 2017 .

SNPs and Haplotypes in DPYD and Outcome of Capecitabine–Response

J. Schellens, M. Deenen, A. Cats, 2011, Clinical Cancer Research.

Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors

J. Schellens, J. Beijnen, A. Huitema, 2020, Clinical Pharmacokinetics.

Phase I study of seliciclib (CYC202 or R-roscovitine) in combination with gemcitabine (gem)/cisplatin (cis) in patients with advanced non-small cell lung cancer (NSCLC).

J. Schellens, J. Beijnen, D. Rodenstein, 2005 .

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826).

J. Schellens, A. Tan, R. Kurzrock, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

J. Schellens, M. Verheij, J. Schellens, 2019, BMC Cancer.

Liquid chromatographic assay for the protease inhibitor atazanavir in plasma.

J. Schellens, J. Beijnen, A. Huitema, 2006, Biomedical chromatography : BMC.

Bcrp1;Mdr1a/b;Mrp2 Combination Knockout Mice: Altered Disposition of the Dietary Carcinogen PhIP (2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine) and Its Genotoxic Metabolites

Tom F. A. de Greef, Jos H. Beijnen, Luc Brunsveld, 2014, Molecular Pharmacology.

Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors

J. Schellens, J. Beijnen, E. Voest, 2007, Investigational New Drugs.

Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2004, Rapid Communications in Mass Spectrometry.

The effect of complementary and alternative medicines on CYP3A4‐mediated metabolism of three different substrates: 7‐benzyloxy‐4‐trifluoromethyl‐coumarin, midazolam and docetaxel

J. Schellens, H. Rosing, J. Beijnen, 2014, The Journal of pharmacy and pharmacology.

Time-dependent resource use and costs associated with different states of disease in patients diagnosed with HER-2-positive metastatic breast cancer

J. Schellens, J. Severens, J. Raaijmakers, 2013, Breast Cancer Research and Treatment.

A phase I study of E7080 in patients (pts) with advanced malignancies

J. Wanders, J. Schellens, A. Mazur, 2008 .

Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.

J. Schellens, J. Beijnen, U. Jaehde, 2012, Clinical pharmacokinetics.

Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment

J. Schellens, J. Beijnen, A. Huitema, 2016, European Journal of Clinical Pharmacology.

427OPembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study

H. Rugo, J. Schellens, K. Tamura, 2017 .

Phase I pharmacological study of continuous chronomodulated capecitabine treatment

J. Schellens, H. Rosing, J. Beijnen, 2018, Pharmaceutical Research.

Phase I and pharmacokinetic study of Kahalalide F in patients with advanced androgen refractory prostate cancer.

J. Schellens, J. Beijnen, W. Meinhardt, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bis[di‐n‐butyl(tri‐ and tetrafluorobenzoato)]tin oxides: Synthesis, characterization and in vitro antitumour activity

J. Schellens, D. Vos, H. J. Kolker, 2010 .

SELDI-TOF MS serum protein profiles in breast cancer: assessment of robustness and validity.

Marie-Christine W. Gast, E. Rutgers, J. Schellens, 2006, Cancer biomarkers : section A of Disease markers.

Abstract CT103: Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028

J. Schellens, A. Santoro, Jonathan D. Cheng, 2015 .

Sensitive liquid chromatography/tandem mass spectrometry assay for absolute quantification of ITIH4-derived putative biomarker peptides in clinical serum samples.

J. Schellens, J. Beijnen, R. Sparidans, 2010, Rapid communications in mass spectrometry : RCM.

Quantitative aspects of the analysis of the monoclonal antibody trastuzumab using high-performance liquid chromatography coupled with electrospray mass spectrometry.

C. Damen, J. Schellens, H. Rosing, 2008, Journal of pharmaceutical and biomedical analysis.

Phase I and pharmacokinetic evaluation of enzastaurin combined with gemcitabine and cisplatin in advanced cancer.

J. Schellens, J. Beijnen, E. Voest, 2006, Journal of Clinical Oncology.

Therapeutic drug monitoring of non-anticancer drugs in cancer patients.

J. Schellens, J. Beijnen, M. Joerger, 2004, Methods and findings in experimental and clinical pharmacology.

Abstract P2-16-14: Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific PI3K inhibitor in combination with fulvestrant: Results from a phase I study

J. Berlin, J. Baselga, D. Juric, 2013 .

Phase II study with Wee1 inhibitor AZD1775 plus carboplatin in patients with p53 mutated ovarian cancer refractory or resistant (<3 months) to standard first line therapy.

D. Jong, J. Schellens, J. Beijnen, 2015 .

Ultrasensitive Bioanalytical Assays for Cytotoxic Drugs: Focus on Locally Administered Anti-Cancer Agents

J. Schellens, H. Rosing, J. Beijnen, 2008 .

Quantification of docetaxel and its metabolites in human plasma by liquid chromatography/tandem mass spectrometry.

A. C. Dubbelman, J. Schellens, H. Rosing, 2013, Rapid communications in mass spectrometry : RCM.

Serum β-HCG and CA-125 as Tumor Markers in a Patient with Osteosarcoma: Case Report

D. de Jong, J. Wanders, J. Schellens, 2011, Tumori.

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.

M. Decramer, J. Schellens, J. Schellens, 2001, European journal of cancer.

Challenges of oral chemotherapy.

J. Schellens, 2005, Clinical advances in hematology & oncology : H&O.

Concomitant Methotrexate Patients Treated with Voriconazole and Severe Skin Toxicity in Pediatric Oncology

J. Schellens, A. Huitema, N. Eijkelenburg, 2014 .

Abstract P6-16-04: Phase 1/2a study of glutathione PEGylated liposomal doxorubicin (2B3-101) in breast cancer patients with brain metastases

A. Jager, J. Schellens, C. Anders, 2015 .

The pharmacokinetic behavior of the photosensitizer meso-tetra-hydroxyphenyl-chlorin in mice and men

M. Ruevekamp, F. Stewart, J. Schellens, 2007, Cancer Chemotherapy and Pharmacology.

Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.

J. Schellens, J. Beijnen, J. Schellens, 2000, Journal of the National Cancer Institute.

A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer

L. V. van't Veer, L. J. Veer, M. Hauptmann, 2011, British Journal of Cancer.

Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer

M. J. van den Bent, J. Verweij, J. Schellens, 2003, British Journal of Cancer.

Liquid chromatography-tandem mass spectrometric assay for pravastatin and two isomeric metabolites in mouse plasma and tissue homogenates.

J. Schellens, J. Beijnen, A. Schinkel, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).

J. Wanders, J. Schellens, V. Grünwald, 2003, European journal of cancer.

The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients

J. Schellens, H. Rosing, J. Beijnen, 2001, British Journal of Cancer.

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

C. Punt, J. Schellens, J. Beijnen, 2011, Clinical Cancer Research.

DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update

J. Schellens, J. Beijnen, J. Schellens, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives.

R. Tollenaar, P. Kuppen, C. V. D. van de Velde, 2004, European journal of cancer.

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours

J. Schellens, M. D. de Jonge, M. Langenberg, 2018, British Journal of Cancer.

Inductively coupled plasma mass-spectrometric determination of platinum in excretion products of client-owned pet dogs.

J. Schellens, J. Beijnen, J. D. de Vos, 2015, Veterinary and comparative oncology.

The performance of model-based versus rule-based phase I clinical trials in oncology

J. Schellens, J. Beijnen, A. Huitema, 2016, Journal of Pharmacokinetics and Pharmacodynamics.

Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling

Marie-Christine W. Gast, Jos H Beijnen, Marie-Christine W Gast, 2008, BMC Medical Genomics.

Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS.

Marie-Christine W. Gast, E. Rutgers, J. Schellens, 2009, Oncology reports.

BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer.

J. Desai, E. Van Cutsem, J. Schellens, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Characterization of Absorption, Metabolism, and Elimination of Niraparib, an Investigational Poly (ADP-Ribose) Polymerase Inhibitor, in Cancer Patients

J. Schellens, H. Rosing, J. Beijnen, 2017 .

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

J. Wanders, J. Schellens, J. Beijnen, 2012, British Journal of Cancer.

Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.

T. Zander, J. Machiels, J. Schellens, 2016 .

Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.

J. Schellens, J. Beijnen, R. Mathijssen, 2015, British journal of clinical pharmacology.

Assessment of clinical activity of E7080, a multitargeted kinase inhibitor, in patients with advanced melanoma treated in two phase I trials.

J. Nemunaitis, J. Schellens, R. Kurzrock, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option

J. Schellens, J. Beijnen, J. Schellens, 2014, British Journal of Cancer.

A Phase 1 Comparative Pharmacokinetic and Cardiac Safety Study of Two Intravenous Formulations of CO‐101 in Patients With Advanced Solid Tumors

J. Schellens, H. Rosing, J. Beijnen, 2013, Journal of clinical pharmacology.

Development, validation, and clinical application of a high‐performance liquid chromatography‐tandem mass spectrometry assay for the quantification of total intracellular &bgr;‐decitabine nucleotides and genomic DNA incorporated &bgr;‐decitabine and 5‐methyl‐2′‐deoxycytidine

J. Schellens, H. Rosing, J. Beijnen, 2019, Journal of pharmaceutical and biomedical analysis.

Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry.

J. Schellens, H. Rosing, J. Beijnen, 2014, Journal of pharmaceutical and biomedical analysis.

Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.

J. Verweij, J. Schellens, G. Schwartz, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Bioanalysis and preliminary pharmacokinetics of the acridonecarboxamide derivative GF120918 in plasma of mice and humans by ion-pairing reversed-phase high-performance liquid chromatography with fluorescence detection.

J. Schellens, J. Beijnen, O. van Tellingen, 2001, Journal of chromatography. B, Biomedical sciences and applications.

Population pharmacokinetics of the novel anticancer agent KRN7000

G. Giaccone, C. Punt, J. Schellens, 2002, Cancer Chemotherapy and Pharmacology.

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

J. Larkin, M. Venturi, J. Schellens, 2014, Clinical Cancer Research.

Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma.

J. Schellens, J. Beijnen, A. Schinkel, 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

J. Schellens, J. Beijnen, A. Huitema, 2010, Clinical pharmacokinetics.

Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care

J. Schellens, J. Beijnen, A. Huitema, 2014, Therapeutic drug monitoring.

Pharmacogenetic factors predicting the need for a higher dose of imatinib.

J. Schellens, D. Goldstein, R. Mathijssen, 2010 .

New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine

J. Schellens, J. Beijnen, D. Pluim, 2008, Molecular Cancer Therapeutics.

Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.

J. Schellens, H. Guchelaar, H. Gelderblom, 2016, European journal of cancer.

Concise drug review: azacitidine and decitabine.

J. Schellens, J. Beijnen, Ellen J B Derissen, 2013, The oncologist.

OA13.03 Long-Term Overall Survival for Patients with Malignant Pleural Mesothelioma on Pembrolizumab Enrolled in KEYNOTE-028

J. Schellens, A. Santoro, Juanita Lopez, 2017 .

Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors

J. Schellens, E. Voest, H. Verheul, 2010, Clinical Cancer Research.

The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases

J. Schellens, H. Rosing, J. Beijnen, 2018, European Journal of Clinical Pharmacology.

Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.

J. Schellens, H. Rosing, J. Beijnen, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical experience with aurora kinase inhibitors: a review.

J. Schellens, J. Beijnen, D. Boss, 2009, The oncologist.

Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil.

J. Schellens, H. Rosing, J. Beijnen, 2015, Journal of pharmaceutical and biomedical analysis.

Concise drug review: pazopanib and axitinib.

J. Schellens, J. Beijnen, R. van Geel, 2012, The oncologist.

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

J. Schellens, J. Beijnen, M. Deenen, 2011, The oncologist.

Does tumour uptake of Foscan determine PDT efficacy?

O. Dalesio, H. Oppelaar, M. Ruevekamp, 1997, International journal of cancer.

A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers.

J. Schellens, P. Elvin, G. Batist, 2015 .

Development of farnesyl transferase inhibitors: a review.

J. Schellens, J. Beijnen, N. Appels, 2005, The oncologist.

Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study

J. Schellens, J. V. van Sandick, A. Aalbers, 2017, JMIR research protocols.

Application of PET/CT in the development of novel anticancer drugs.

J. Schellens, J. Beijnen, D. Boss, 2008, The oncologist.

Pharmacodynamic evaluation of pCDC2 as the target engagement biomarker to assess activity of MK-1775 a Wee1 tyrosine kinase inhibitor.

A. Oza, G. Shapiro, J. Schellens, 2012 .

Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.

J. Schellens, J. Beijnen, H. Boot, 2013, International journal of radiation oncology, biology, physics.

Cancer Therapy: Clinical Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

J. Schellens, R. Rueger, M. Scheulen, 2012 .

Abstract CT050: A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors

J. Schellens, J. Tabernero, M. Alsina, 2016 .

Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer.

J. Schellens, J. Beijnen, I. Meijerman, 2008, Cancer treatment reviews.

The absolute quantification of eight inter‐α‐trypsin inhibitor heavy chain 4 (ITIH4)‐derived peptides in serum from breast cancer patients

Marie-Christine W. Gast, J. Schellens, J. Beijnen, 2010, Proteomics. Clinical applications.

Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck?

A. V. van Kuilenburg, J. Schellens, R. Danesi, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine‐associated toxicity

U. Amstutz, J. Schellens, J. Beijnen, 2016, International journal of cancer.

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors

J. Schellens, E. Voest, H. Verheul, 2008 .

Is rectal administration an alternative route for imatinib?

J. Schellens, H. Guchelaar, H. Gelderblom, 2007, Cancer Chemotherapy and Pharmacology.

High-Tech Drugs in Creaky Formulations

J. Schellens, J. Beijnen, B. Nuijen, 2017, Pharmaceutical Research.

Individual PK-guided sunitinib dosing: A feasibility study in patients with advanced solid tumors.

S. Sleijfer, J. Schellens, J. Beijnen, 2012 .

P‐glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel

J. Schellens, H. Rosing, J. Beijnen, 2013, International journal of cancer.

Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study

J. Schellens, J. Beijnen, R. Mathijssen, 2019, Pharmaceutical Research.

Cisplatin-Resistant Subline of a Human Ovarian Cancer Cell Line

J. Schellens, G. Stoter, H. J. Kolker, 1995 .

Development of an extended-release formulation of capecitabine making use of in vitro-in vivo correlation modelling.

J. Schellens, J. Beijnen, A. Huitema, 2014, Journal of pharmaceutical sciences.

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours

J. Wanders, J. Schellens, J. Beijnen, 2008, British Journal of Cancer.

926 Pharmacokinetics (PK), clinical pharmacodynamics (PD) and safety of chronic oral topotecan (T), in a phase I study

J. Verweij, J. Schellens, W. Loos, 1995 .

Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.

J. Schellens, H. Rosing, J. Beijnen, 2011, Journal of analytical toxicology.

A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A

J. Schellens, H. Rosing, J. Beijnen, 2001, Cancer Chemotherapy and Pharmacology.

Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer

S. Jaeger, J. Schellens, H. Lenz, 2015 .

An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma.

H. Ovaa, J. Schellens, H. Rosing, 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

CEA-targeted engineered IL2: Clinical confirmation of tumor targeting and evidence of intra-tumoral immune activation.

G. Coukos, T. Nayak, J. Tabernero, 2015 .

Clinical Pharmacokinetics of Vemurafenib in BRAF‐Mutated Melanoma Patients

J. Schellens, H. Rosing, J. Beijnen, 2017, Journal of clinical pharmacology.

Dried Blood Spot Self-Sampling at Home for the Individualization of Tamoxifen Treatment: A Feasibility Study.

S. Linn, J. Schellens, H. Rosing, 2015, Therapeutic drug monitoring.

Determination of tamoxifen and endoxifen in dried blood spots using LC-MS/MS and the effect of coated DBS cards on recovery and matrix effects.

J. Schellens, H. Rosing, J. Beijnen, 2014, Bioanalysis.

Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry.

J. Schellens, J. Beijnen, R. Sparidans, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.